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Exposure to ionizing radiation contributing to negative health outcomes is 
a widespread concern among the public, scientific community, and workers in the 
nuclear energy industry and diagnostic imaging field. However, the impact of 
sub-lethal exposures remains contentious particularly in pregnant women who 
represent a vulnerable group. The fetal programming hypothesis states that an 
adverse in-utero environment or stress during development of an embryo or fetus 
can result in permanent physiologic changes often resulting in progressive 
metabolic dysfunction with age. Various models of fetal programming present 
similar outcomes with offspring demonstrating alterations in birth weight. Low 
birth weight predisposes offspring to insulin resistance and impaired glucose 
metabolism. To assess the effects of sub-lethal dose radiation on fetal 
programming of glucose metabolism, pregnant C57Bl/6J mice were irradiated at 
1000 mGy and compared to a sham irradiated group. Female offspring born to 
dams irradiated at 1000 mGy had: 1) increased liver weights, 2) increased 
hepatic protein expression of suppressor of cytokine signaling 3 (SOCS3) and 
phosphoenolpyruvate carboxykinase (PEPCK), and 3) increased 18F-
fluorodeoxyglucose (18F-FDG) uptake in interscapular brown adipose tissue 
(IBAT) measured by positron emission tomography (PET). Male offspring born to 
irradiated dams showed non-significant reductions in SOCS3 and PEPCK protein 
expression in the liver and increased hepatic triglycerides. Radiation exposure to 
1000 mGy caused no change in plasma triglycerides, however significant sex 
differences were observed. Female IBAT phosphorylated protein kinase B (Akt) 
to total Akt ratio and phosphorylated glycogen synthase kinase 3 beta (GSK3b) 
to total GSK3b ratio did not increase significantly with treatment suggesting 
insulin signaling is not responsible for the increase in tissue specific 18F-
fluorodeoxyglucose (18F-FDG) uptake. It is likely that the b-adrenergic pathway is 
responsible for the increased IBAT glucose uptake observed in the female 
offspring from the increase in phosphorylated GSK3b and uncoupling protein 1 
(UCP1) protein expression. While non-significant, these measures account for 
only a single time point in the rodent lifespan. The results of this study indicate 
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alterations in glucose uptake and metabolism are significant in mice at 4 months 
of age. These findings suggest that sub-lethal dose radiation alters glucose 












































Lay Summary  
Faculty and students in the Department of Biology at Lakehead University 
are bound together by a common interest in explaining the diversity of life, the fit 
between form and function, and the distribution and abundance of organisms. 
This research supplements the lack of data available for the physiological effects 
of a sub-lethal dose of radiation exposure during pregnancy on the fetus when it 
reaches adult life. Changes caused by radiation may not be present at birth or 
visible making it difficult to detect alterations. With age, the development and 
progression of metabolic disease is a potential outcome. Little is known about 
metabolic changes that occur due to sub-lethal radiation exposure and if they 
present a risk or can be beneficial. While C57Bl/6J mice are considered 
radioresistant, a sub-lethal dose of radiation to these mice is assumed to be 
equivalent to a low dose exposure in humans. The findings of this study suggest 
that insulin resistance may result from sub-lethal radiation exposure in mice. 
Increased glucose uptake in interscapular brown adipose tissue (IBAT) is usually 
beneficial as it indicates increased energy expenditure, correlates inversely with 
body mass index and is a target for lowering the prevalence of obesity. In this 
study, it may be an indicator of compensation for alterations in glucose 
metabolism. Sexual dimorphism was apparent suggesting that female offspring 
are more susceptible to alterations in glucose metabolism that will likely become 
more pronounced with age. The results from this study may provide knowledge 
that is translatable from mice to humans to add to the knowledge necessary for 
setting standards for radiation protection and ease concerns about radiation 
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Chapter 1. Introduction  
1.1 Statement of Problem  
Exposure to ionizing radiation and the possibility of radiation contributing to 
negative health outcomes is a widespread concern. The public, scientific 
community, and workers, specifically in the nuclear energy industry and 
diagnostic imaging, are exposed to different sources of radiation. Pregnant 
women represent a vulnerable group and are sometimes exposed to radiation 
during diagnostic imaging if the woman is not aware of the pregnancy or in 
emergency situations. Effects of exposure on the fetus are dependent on 
gestational age and absorbed radiation dose. The fetal programming hypothesis 
which states that an adverse in-utero environment or stress during development 
of an embryo or fetus can result in permanent physiologic changes [1], which 
often result in progressive metabolic dysfunction with age.  
The body uses glucose as a main source of energy. Glucose metabolism 
must be tightly regulated to maintain proper organ function. In response to 
postprandial glucose, b-cells in the pancreas sense changes in plasma glucose 
levels and release the hormone insulin, stimulating glucose uptake and 
metabolism in adipose tissue and liver [2].  
In the liver, insulin binds to insulin receptors leading to cell signaling events 
that regulate glucose metabolism. Insulin stimulates glucose uptake, 
glycogenesis, and glycolysis while inhibiting the production of glucose through 
gluconeogenesis and glycogenolysis [2]. Glucose and lipid metabolism are 
closely related. Alterations in glucose metabolism can lead to insulin resistance, 
a condition where b-cells in the pancreas produce insulin in response to glucose 
but cells are unable to respond to the insulin effectively leading to hyperglycemia. 
This can be caused by defects in the insulin signaling pathway. Type 2 diabetes, 
obesity, and non-alcoholic fatty liver disease are associated with insulin 
resistance [3]. An alternative energy source for the liver, in times of glucose 
deficiency, are triglycerides which have been stored through lipogenesis [4]. 
However, accumulation of hepatic or circulating triglycerides from an imbalance 
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in de novo lipogenesis/lipid uptake and lipid disposal leads to adiposity which is 
linked to obesity and metabolic syndrome [5], [6].  
The role of brown adipose tissue (BAT) in energy homeostasis and 
metabolism is a growing area of interest after advancements in technology have 
identified BAT in adult humans. It was originally thought to be present only in 
infants and small animals. BAT is responsible for non-shivering thermogenesis 
through uncoupling protein 1 (UCP1) which uncouples oxidative phosphorylation 
resulting in heat production rather than ATP formation [7]. Recently, BAT has 
been identified as an endocrine organ with a role in regulating metabolism [8]. 
Transplant studies have shown that increasing the amount of BAT in rodents 
results in increased glucose uptake and improved insulin sensitivity in 
endogenous BAT, white adipose tissue and the heart [9]. In humans, the amount 
of BAT is inversely related to body mass index (an indicator of obesity) [10], [11].   
 
1.2 Significance of Study 
There are several established models of fetal programming that induce in-
utero stress including maternal undernutrition, protein-restricted diets, maternal 
obesity, prenatal hypoxia, and exposure to stress hormones like glucocorticoids. 
These models present similar outcomes with the offspring demonstrating 
alterations in birth weight followed by weight normalization within the first few 
months. Intrauterine growth restriction and low birth weight seem to predispose 
offspring to insulin resistance and impaired glucose metabolism [12]–[14]. 
Glucocorticoid exposure, maternal obesity, and maternal undernutrition or diet 
restriction predispose animals to alterations in metabolism and insulin resistance 
[15]–[18]. Prenatal hypoxia contributes to cardiovascular disease development in 
adulthood [19]. Maternal obesity fetal programming models are associated with 
offspring insulin resistance and increased adiposity [20]. Overall, a poor maternal 




Diagnostic radiation exposure may be a potential cause of increased cancer 
risk [21]. Moreover, pregnant women represent a more vulnerable population 
[22]. The effect of radiation on the fetus has been studied through animal studies 
and from atomic bomb exposure [23]. Radiation exposure in the third trimester of 
pregnancy, has been reported to result in behavioural, social, and locomotor 
changes in the offspring in adulthood as well as the appearance of microcephaly 
[24], [25]. However, little is known about the effects of sub-lethal dose radiation 
(SLDR) on fetal programming of glucose metabolism and glucose uptake. 
Alterations to metabolism at young age are thought to contribute to severe 
metabolic dysfunction in later life. First, we must understand the impact of 
radiation in sub-lethal doses to understand the risks for various exposures. 
 
1.3 General Research Question  
Does SLDR exposure in the third trimester of pregnancy alter glucose 
metabolism of the offspring?  
 
1.4 Specific Aims 
1. Determine the effects of SLDR on glucose metabolism in the liver.  
 
Rationale: 
Insulin sensitive tissues such as the liver are susceptible to insulin 
resistance. Alterations in hepatic glucose metabolism can lead to impaired whole 
body glucose metabolism, insulin resistance, type 2 diabetes, obesity, and 
metabolic syndrome. Low birth weight is predictive of insulin resistance. Stress 
models of fetal programming have shown increases in gluconeogenesis and 
increases in protein expression of proteins involved in gluconeogenesis when 
offspring had low birth weights [29], [30]. Radiation presents a stress event that 
may have similar affects. Measuring the expression of proteins in the liver 
associated with insulin resistance such as suppressor of cytokine signaling 3 
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(SOCS3) and phosphoenolpyruvate carboxykinase (PEPCK), can indicate 
alterations in hepatic glucose metabolism.  
 
Hypotheses:  
SLDR will cause alterations in glucose metabolism and an accumulation of 
hepatic triglycerides in offspring.  
 
2. Determine the effects of SLDR on interscapular brown adipose tissue (IBAT) 
glucose uptake in vivo. 
 
Rationale: 
BAT activity is linked to increased energy expenditure, glucose utilization 
from the bloodstream and stored lipid use. In BAT, glucose uptake indicates 
metabolically active tissue. IBAT glucose uptake can be measured in vivo using 
microPET imaging with 18F-fluorodeoxyglucose (18F-FDG). A compensatory 
increase in BAT activity is observed in fetal programming models of protein 
restriction [26]. Plasma triglyceride levels have been shown to decrease with 
increased BAT activity [27], [28]. 
 
Hypotheses: 
SLDR will cause an increase in IBAT glucose uptake to compensate for 
impaired whole-body glucose metabolism. SLDR will also decrease plasma 
triglycerides.  
 
3. Determine the effects of SLDR on cell signaling in BAT. 
 
Rationale: 
BAT is regulated by insulin signaling, however, it seems that BAT activity 
is primarily regulated via b-adrenergic signaling [31]–[34]. Studies have reported 
that BAT activity can be restored or enhanced by using β-adrenergic receptor 
agonists [32], [34]. Data from our laboratory, observed majority of basal BAT 
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activity to be b-adrenergic mediated but it is responsive to insulin. By looking at 
targets from each of the pathways, we can determine the method of action 
leading to alterations in glucose uptake. Protein kinase B (Akt) will be used as an 
insulin signaling pathway target. Glycogen synthase kinase 3 beta (GSK3b) is 
involved in both the β-adrenergic signaling and insulin signaling pathways. By 
combining the data for Akt and GSK3b protein expression and phosphorylation 
status, the pathway responsible for the increased glucose uptake in IBAT can be 
suggested. BAT activity can also be measured by UCP1 expression as increased 
UCP1 is an adaptation to chronic BAT activity [26].  
 
Hypotheses: 
Exposure to SLDR will result in an increase in the phosphorylation of 
GSK3b but no change in the phosphorylation of Akt suggesting increased BAT 
activity is a result of increased b-adrenergic signaling. SLDR exposure will result 













Chapter 2. Literature Review  
2.1 Fetal Programming  
Environmental effects in-utero have long term influences on health 
outcomes in later life. The fetal programming hypothesis describes the concept 
that adult disease can originate from in-utero programming during development 
when internal or external environmental conditions are suboptimal [1]. This 
results in permanent physiologic changes that lead to progressive metabolic 
dysfunction with age [1]. Stress events cause a fight-or-flight response in the 
mother that trigger the hypothalamic-pituitary-adrenal (HPA) axis to produce 
hormones capable of crossing the placenta and affecting the fetus [35]. Stress is 
thought to cause permanent modification of the HPA axis [36]. Xiong and Zhang 
2013, review the role of the HPA axis and how alteration in its activity can be 
detrimental to the fetus and affect developmental processes [37]. That means 
fetal growth and development are dependent on the mother’s nutritional, 
hormonal, and metabolic environment.  
Epidemiological studies have consistently shown a relationship between 
high or low birth weights and development of disease in adulthood [38], [39]. 
Low birth weight can occur because of preterm delivery or intrauterine growth 
restriction (IUGR) caused by substrate limitation to the embryo or fetus. The 
thrifty phenotype hypothesis links poor fetal and infant growth to changes in 
glucose metabolism leading to increased risk of metabolic disorders such as 
metabolic syndrome and type 2 diabetes [40], [41]. Studies focusing on 
maternal obesity and high-fat diets have found that elevated birth weight 
offspring are also at risk [39], [42]. Fetal programming has been demonstrated 
in several species, including sheep, baboons, guinea pigs, rats, and mice, 
using a range of techniques to induce alterations in offspring birth weight 
including exposure to stress hormones, maternal diet, and maternal 




2.1.1 Models of Fetal Programming 
2.1.1.1 Maternal Nutrition  
The fetus responds to poor maternal nutrition from maternal protein 
restriction or undernutrition by activating adaptive processes. Undernutrition is 
associated with obesity, insulin resistance, and type 2 diabetes [43]–[45]. 
Similarly, models of maternal nutritional excess, like high-fat diets, lead to an 
offspring phenotype that resembles metabolic syndrome with impaired glucose 
metabolism, increased plasma triglycerides, and increased adiposity [46], [47]. 
Offspring of obese dams that continue to consume a high-fat diet display 
features of metabolic syndrome and have increased lipid accumulation in the 
liver [48], [49]. Metabolic effects are more pronounced in female offspring [49]. 
These offspring are more likely to develop insulin resistance in later life, and 
more likely to give birth to overweight babies.  
 
2.1.1.2 Prenatal Hypoxia  
Prenatal hypoxia is a model of fetal programming where the fetus lacks 
the appropriate level of oxygen required for development. This can be caused 
by the mother travelling to high altitudes, or conditions like pre-eclampsia [50]. 
Risks are higher when exposure occurs in the second and third trimester of 
pregnancy because the early stages of pregnancy occur under anaerobic 
conditions anyway [19]. The main consequence of prenatal hypoxia in humans 
and rodents appears to be IUGR [51]–[53]. The fetus does not grow to its full 
potential and is born small for their gestational age leading to early onset of 
adult diseases.  
 
2.1.1.3 Stress Hormones  
Cortisol is a glucocorticoid hormone important for development and 
maturation in late gestation. Glucocorticoids control the HPA axis, a negative 
feedback loop that stimulates glucose metabolism, promotes fatty acid release, 
and inhibits protein synthesis [54], [55]. Stress models of fetal programming use 
excess endogenous or synthetic glucocorticoids, such as dexamethasone or 
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betamethasone, which permanently alter HPA axis function [36]. Fetal exposure 
to glucocorticoids are thought to alter the function of the HPA axis and to 
contribute to insulin resistance in later life [29]. Dexamethasone is known to 
cause IUGR and glucose intolerance in adult offspring [29]. Changes are also 
seen in the liver and in circulating levels of leptin, insulin, and corticosterone [29]. 
While hepatic glycogen content and glycogen phosphorylase expression remain 
unchanged, overexpression of hepatic gluconeogenic enzyme 
phosphoenolpyruvate carboxykinase (PEPCK) is frequently observed and 
thought to be responsible for increasing gluconeogenesis [29], [56].  
 
2.1.1.4 Radiation Exposure  
There is a lack knowledge on the effects of low dose radiation (LDR) or 
sub-lethal dose radiation (SLDR) on fetal programming of metabolism. What is 
known comes from animal studies and the aftermath of the atomic bombs and 
measures are limited to small head size observed in children, intelligence 
quotients, and behavioural and locomotor changes observed as adults [23], 
[57]–[60]. Mechanisms of how LDR and SLDR effect the fetus remain 
unknown.  
 
2.2 Ionizing Radiation Exposure  
Radiation is classified as ionizing or non-ionizing. Non-ionizing radiation 
sources include ultraviolet (UV) rays from the sun or tanning beds, and 
electromagnetic radiation from radio waves and microwaves [61]. Ionizing 
radiation has more energy than non-ionizing radiation, enough to remove 
electrons from an atom. Ionizing radiation can be direct, caused by alpha or 
beta particles, or indirect, caused by gamma rays or X-rays [61]. Gamma and 
X-rays are more penetrating and can cause more biological damage. Damage 
can include inducing oxidative stress resulting in DNA methylation, DNA bond 
breakage, or post-translational histone modifications [61]. These modifications 
can affect gene expression profiles that may lead to either adaptive processes 
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or progression of disease reviewed in more detail by Tharmalingam et al. 2017 
[62], and Lee 2015 [63].  
 
2.2.1 Radiation Exposure in Humans  
The Canadian Nuclear Safety Commission’s Radiation Protection 
Regulations sets an annual dose limit of 1 mSv for the public and 50 mSv for 
nuclear energy workers [64]. Table 1 summarizes the health effects and limits at 
certain absorbed radiation doses. Responses to radiation can vary between 
individuals based on radiation source, radiation dose, length of exposure, and 
genetic makeup. High doses of radiation are rare outside of radiotherapy and 
nuclear disasters whereas low dose radiation exposure is much more common 
[65]. Less is known about the outcomes from LDR exposure. LDR can come from 
occupational exposures, diagnostic imaging, cancer therapy, natural areas of 
high background (radon), and space travel (airplanes). The existing guidelines 
attempt to limit the exposure of workers in nuclear and medical industries but 
there is still concern. Scientific evidence of risks and/or benefits from LDR are 
lacking. Linear no-threshold model has been used to extrapolate detrimental 
health effects in humans from LDR, less than 100 mSv [66]. Extrapolation from 
high-dose effects may not necessarily reflect the biological outcomes at low 
doses. For example, the model doesn’t account for biological defense 












Table 1. Health effects and limits of radiation from the Canadian Nuclear Safety 
Commission [67]. 
Dose (mSv) Health Effect or Limit in Humans 
Greater than 5000 May lead to death when received all at once 
1000 May cause symptoms of radiation sickness if 
received within 24 hours  
100 Lowest acute dose known to cause cancer  
30-100 Radiation dose from a full body CT scan 
50 Annual radiation dose limit for nuclear workers  
1.8 Average annual Canadian background 
exposure 
1 Annual public radiation dose limit 
0.1-0.12 Dose from lung X-ray  
0.01 Dose from dental X-ray, average annual dose 
due to air travel  
Radiation is commonly measured in gray (Gy) which is a unit of absorbed dose 
reflecting the energy distributed into the mass of tissue or sieverts (Sv) which is 
the biological equivalent dose, taking into account the amount and type of 
radiation. 1000 mSv is equal to 1000 mGy. 
 
 
The possibility exists that exposure to low dose radiation may be 
beneficial. Studies have shown that exposure to doses less than 100 mGy act as 
a primer and may have protective effects on subsequent high dose radiation 
exposure [68], [69]. Without more evidence of the benefits from LDR in humans, 
there remains concern over the perceived increased risk of developing cancer.  
 
2.2.2 Radiation Exposure in Mouse Models  
Compared to humans, mice require a higher radiation dose for similar 
health effects to be observed. Animal studies on ionizing radiation have 
categorized doses of radiation as ultra-low, low, and high. Ultra-low radiation is 
characterized as a dose less than 1 mGy. United Nations Scientific Committee 
on the Effects of Atomic Radiation classifies low dose radiation as any dose 
below 100 mGy [70]. High doses vary significantly ranging from 2000 mGy to 
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50,000 mGy. The higher doses are usually accumulated during multiple 
exposures over time rather than a one-time whole-body exposure.  
There are major differences in mouse strain radiation sensitivity. Radiation 
sensitivity is referenced as LD50:30 which is the dose of whole-body radiation 
that is lethal to 50% of the target population by 30 days after exposure. Grahn 
and Hamilton 1956, demonstrated C57Bl/6 mice to have an LD50:30 of 6300 ± 
40 mGy and consider this strain to be radioresistant [71]. In comparison, BALB/c 
mice are considered radiosensitive with an LD50:30 of 5000 ± 60 mGy. In 
humans, the LD50:30 is approximately 4500 mGy [72]. With this knowledge, the 
amount of radiation can be adjusted to be comparable to the doses and 
physiological risks in humans. For the present study, a dose of 1000 mGy was 
chosen for C57Bl/6J mice. This dose is frequently used in LDR studies when 
looking at a dose response as a comparable high dose (Table 2). Rather than 
attempting to classify 1000 mGy as high or low dose, for the purposes of this 
study, 1000 mGy will be considered a sub-lethal dose.  
 
2.2.3 Radiation Exposure During Pregnancy  
Pregnant women represent a population that is more vulnerable to 
radiation exposure. There is concern for both the mother and the unborn child. 
The risks of prenatal exposure to ionizing radiation are dependent on the 
absorbed dose and timing of exposure related to gestational age [21], [73], 
[74]. During the first trimester, radiation risks are most significant. High doses 
of radiation exposure during the pre-implantation stage can result in failure to 
implant leading to abortion. Russel (1950) studied radiation at doses of 1000-
4000 mGy during the pre-implantation stage (days 0-5 of gestation) in pregnant 
mice and found an “all-or-nothing” effect where the doses were either lethal or 
had no effects at all [75], [76]. If the embryo survives the exposure, it will likely 
fully develop and have low risk of congenital abnormalities. It is generally 
accepted that exposures to low doses during the first two weeks of pregnancy 
may cause damage that can be compensated for or repaired [77], [78]. Low 
doses are detrimental during organogenesis (weeks 2 – 8). There are 
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increased risks of malformations, growth restriction, and behavioural or motor 
skill deficits discussed by De Santis et al. 2007 [79]. Radiation risks are 
somewhat less in the second trimester [80]. The third trimester, or late 
gestation, is a critical stage where cells can be influenced by changes in the in-
utero environment resulting in adaptations in cellular function [81]–[83]. 
 
2.2.4 Prenatal Radiation Exposure in Humans 
High dose ionizing radiation exposure is known to be mutagenic and 
carcinogenic. Health effects from high dose radiation exposure in humans are 
documented from events like the Chernobyl disaster and the atomic bombings of 
Hiroshima and Nagasaki. Data for prenatal exposures comes predominantly from 
survivors of the atomic bombs that were pregnant at the time and within 2000 
metres of the hypocenter. Individuals closer to the hypocentre at the time of the 
explosion received higher radiation doses and negative health effects were more 
common [84], [85]. Fetal exposure doses were estimated from this information. 
Reports show children that were exposed in-utero have increased incidence of 
mental impairments marked by reductions in intelligence quotient score based on 
informed clinical opinion, microcephaly, growth restriction, and childhood thyroid 
cancer [84], [86], [87]. From these cases, microcephaly and mental impairments 
appear to be independent of each other. Reports of microcephaly are higher 
when the exposure occurred during the first and second trimester compared to 
third trimester [86].  
Less is known about the effects of LDR exposure. Several studies 
suggest negative health effects from LDR exposure from medical diagnostic 
imaging like computed tomography scans [88], [89]. There is evidence of a 
positive relationship between long term exposure to LDR and leukemia [90]. 
But there are limitations to these studies and as such require further 
exploration to understand the full effect of LDR on humans and animals. 
Another factor to consider when conducting these studies is that the dose 
delivered to the fetus is thought to be lower than what the mother is exposed to 
and likely falls below the threshold dose for deterministic effects [91]. With 
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limited data available for LDR exposure in humans, researchers have turned to 
animal models to assess radiation effects. 
 
2.2.5 Prenatal Radiation Exposure in Rodent Models  
Mouse models require higher radiation doses than humans to produce 
similar morphological and physiological changes. The short life span of mice 
makes it easy to track changes of long-term effects. Like humans, the day of 
radiation exposure during gestation is important. Studies have found that 
irradiation on day 14 of gestation is high risk for locomotor function and 
behavioural changes [92], [93]. The brain is developing during the third trimester 
and therefore, radiation exposure during gestation day 13-18 has detrimental 
effects on the brain [93]. Day of experiment to test changes is important because 
some effects exist at an early age and become unobservable later in life or vice 
versa. Behavioural changes in mouse models initially measured at 6 months of 
age appear to persist to 12 months but are no longer observed at 18 months old 
[94]. Chromosomal instability was observed in bone marrow at doses of 500 mGy 
and higher at 12 months old and has been suggested as a mechanism for the 
progression of leukemia [95]. In majority of LDR studies, health affects get worse 
around 12 months of age and disappear by 18 months (Table 2).  
Dose response relationships are observable for brain weight, body weight, 
behavioural changes, learning function, and memory retention [92]–[94], [96], 
[97]. Other stressful events, like restraining the animal while irradiating without 
the use of anesthesia, could have induced changes presumed to be from 
radiation. Effects of gamma radiation at doses of 100 to 3000 mGy in mouse 
models are summarized in Table 2. While there is evidence of neurological and 
behavioural changes, there is no data available for the effects of LDR on 







Table 2. Prenatal ionizing radiation exposure from gamma radiation in mouse 
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Overall, there is no consensus on what is a high versus low dose of 
radiation when it comes to fetal programming. The dose of absorbed radiation 
from a whole-body exposure by the mother may not be the same as the dose 
that reaches the fetus. Negative or positive effects of SLDR in animal models 
may elucidate mechanisms responsible for LDR fetal programming in humans 
and provide information for prevention or therapeutic intervention.  
 
2.3 Brown Adipose Tissue  
2.3.1 Characteristics and Function 
Until recently, brown adipose tissue was thought to be present in only 
neonates and young children who were not capable of shivering to maintain core 
body temperature upon cold exposure and rely on non-shivering thermogenesis 
of BAT to keep warm. With age, it was thought BAT would transform into white 




Both human and rodent BAT is characterized by brown adipocytes that 
contain multilocular lipid droplets densely packed with mitochondria, rendering 
the tissue brown in colour. The mitochondria contain uncoupling protein 1 
(UCP1), a protein found in BAT but not in WAT, which uncouples oxidative 
phosphorylation resulting in heat production, rather than ATP formation (Figure 
2) [105]. UCP1 allows the transfer of protons from the intermembrane space 
into the mitochondrial matrix dissipating the proton gradient necessary for the 
phosphorylation of ADP to ATP [106].  
 
Figure 2. Uncoupling protein 1 (UCP1). UCP1, a protein found in BAT, is 
responsible for heat production through non-shivering thermogenesis. Located in 
the mitochondrial inner membrane, the electron transport chain generates a 
proton gradient that drives ATP synthesis. Uncoupled oxidative phosphorylation 
through UCP1, brings protons back into the mitochondrial matrix to dissipate the 
proton build up in the intermembrane space. Heat is produced as a by-product. 
Numbers I-IV correspond to electron transport chain complexes with ATP 




UCP1 is activated and expression is increased by the b-adrenergic 
pathway (Figure 3). UCP1 activation also requires the binding of fatty acids but 
this mechanism remains contentious [108]–[111]. It is known that b3-
adrenoreceptor agonists induce UCP1 expression and thermogenesis in rodents 
and isolated brown adipocytes [108], [112]–[114]. b3-adrenoreceptor agonists 
also enhance glucose metabolism in rodents [32], [115]. UCP1 null mice are not 
able to maintain their body temperature when exposed to the cold and develop 





Figure 3. UCP1 is activated in brown adipocytes by b-adrenergic signaling. 
Norepinephrine binds to b3-adrenoreceptors at the cell membrane of brown 
adipocytes triggering a signaling cascade stimulating cyclic adenosine 
monophosphate (cAMP) production. cAMP activates protein kinase A (PKA) 
which stimulates lipolysis. Adipocytes take up fatty acids derived from 
intracellular triglycerides and glucose and form lipid droplets. Fatty acids are 
TG 













released from lipid droplets and combusted by the mitochondria or bind 
allosterically to activate UCP1. Adapted from Kooijman et al. 2015 [117].  
 
Evidence from transplant studies have shown BAT to have a role as an 
endocrine organ releasing endocrine factors, or adipokines, including insulin-like 
growth factor 1, fibroblast growth factor 21, interleukin 6, and neuregulin 4 that 
target peripheral tissues such as WAT, liver, pancreas, and bone. A review 
focused on the adipokines released by BAT can be found in Villarroya et al. [8] 
as it will not be covered here.  
2.4 Metabolism  
2.4.1 BAT Metabolism 
BAT is highly vascularized and innervated by the sympathetic nervous 
system [108], [118]. Its activation is predominantly controlled by b-adrenergic 
signaling [108]. Non-shivering thermogenesis is controlled by the 
hypothalamus where in response to overfeeding or cold exposure, the 
sympathetic nervous system releases norepinephrine which binds to b3-
adrenergic receptors, the most significant type of b-adrenergic receptor in 
mature brown adipocytes (Figure 3) [108]. This results in the activation of its G-
coupled protein. Subsequently, adenyl cyclase stimulates the formation of 
cyclic adenosine monophosphate (cAMP) [108]. cAMP activates protein kinase 
A (PKA) resulting in (1) enhanced synthesis of UCP1 (a marker of 
thermogenesis), (2) increased intracellular lipolysis, and (3) phosphorylation 
and inhibition of glycogen synthase kinase 3 beta (GSK3b). GSK3b inhibition 
will reduce phosphorylation of glycogen synthase decreasing glycogen 
synthesis. 
BAT is an insulin sensitive tissue meaning that it can also be controlled 
by the insulin signaling pathway [119]. Insulin binds to an insulin receptor at the 
plasma membrane inducing a conformational change that leads to the 
phosphorylation of tyrosine residues in the b subunit (Figure 4). The residues 
are recognized by insulin receptor substrates (IRS). Activation of the receptor 
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leads to phosphorylation of tyrosine residues on the IRS proteins that are 
recognized by phosphatidylinositol 3-kinase (PI3K). This leads to a signaling 
cascade that results in protein kinase B (Akt) translocating to the plasma 
membrane where it is activated by phosphorylates. Akt will subsequently 
phosphorylate and inhibit GSK3b decreasing glycogen synthesis [120]. GSK3 
activity is increased in skeletal muscle and adipose tissue in insulin resistance 
states [121], [122]. 
 
 
Figure 4. BAT pathways. BAT is controlled by two pathways: b-adrenergic and 
insulin signaling pathways. Norepinephrine binds to a b-adrenergic receptor 
resulting in a signaling cascade that increases cyclic adenosine monophosphate 
(cAMP) and eventually leads to the phosphorylation and inhibition of glycogen 
synthase kinase 3 beta (GSK3b). Insulin binds to the insulin receptor beginning a 
signaling cascade that results in protein kinase B (Akt) phosphorylating and 
inactivating GSK3b.  
 
BAT can be activated when body temperature decreases or after 
consuming food [123], [124]. BAT uses glucose, intracellular triglycerides and 
free fatty acids from circulation to generate heat to protect against cold exposure 
and burn excess energy to prevent adiposity (Figure 3) [125]. Its activation leads 
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to increased energy expenditure, increased glucose uptake, insulin sensitivity, 
and a decrease in body weight and triglycerides [27]. Therefore, BAT is 
becoming increasingly recognized as a target for obesity and diabetes treatments 
[126]. BAT transplantation studies found that increasing the amount of BAT 
present in mice, increased whole-body and tissue glucose metabolism by 
improving glucose uptake into endogenous BAT, WAT, and heart muscle [9].  
 
2.4.2 Liver Metabolism 
Understanding normal hepatic glucose metabolism is important for 
recognizing metabolic alterations that can result from fetal programming. The 
liver, along with skeletal muscle, is a main site of glucose utilization after a meal. 
Food is digested in the gastrointestinal tract, and glucose, fatty acids, and amino 
acids are absorbed into the bloodstream and transported to the liver through the 
portal vein [2]. Glucose enters liver hepatocytes via GLUT2 transporters located 
at the plasma membrane. Once in the hepatocytes, glucose can (1) enter the 
glycolytic pathway to form ATP, (2) enter the glycolytic pathway to be used in 
fatty acid and triglyceride synthesis in a process called lipogenesis, or (3) be 
stored as glycogen, a process called glycogenesis. Glucose not entering the liver 
on first pass via portal vein goes to other tissues like skeletal muscle.  
The liver is responsible for maintaining normal blood glucose levels. Liver 
metabolic activity is tightly regulated by hormones like insulin. In response to high 
blood glucose levels, or in fed-state, b-cells in the pancreas release insulin into 
the bloodstream stimulating glucose uptake, glycolysis, lipogenesis, and 
glycogenesis. Insulin will inhibit the production of glucose by gluconeogenesis 
and glycogenolysis. Alternatively, when blood glucose levels are low and 
glycogen stores have been depleted, a non-carbohydrate source, like amino 
acids, can be converted into glucose through gluconeogenesis.  
Alterations to any of these pathways can lead to insulin resistance, 
impaired whole-body glucose metabolism, type 2 diabetes mellitus, or metabolic 
syndrome [127], [128]. Insulin resistance occurs when the tissue no longer 
responds to insulin [129]. In the liver, insulin resistance has a collective response 
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involving the increase of gluconeogenesis and glycogenolysis and the reduction 
of glucose uptake and glycogen synthesis. This can lead to hyperglycemia, 
having blood glucose levels above the normal range. Insulin resistance increases 
the risk of developing type 2 diabetes mellitus and is also a symptom of 
metabolic syndrome along with high blood pressure, abdominal obesity, and 
abnormal triglyceride and cholesterol levels [130].  
The liver is involved in many pathways of lipid metabolism. Fatty acids are 
obtained from absorption of dietary fats, from lipolysis in adipose tissue, or de 
novo synthesis in the liver [4]. Once in the liver, fatty acids can be oxidized for 
energy, converted to triglycerides for storage or secreted as very-low density 
lipoprotein [2]. Like glucose metabolism in the liver, lipid metabolism is a tightly 
controlled process, that includes import of lipids into the liver, and lipid oxidation 
or export, to maintain the appropriate balance in the liver.  
Situations where triglycerides or fatty acids accumulate in the liver due to 
an imbalance in lipid storage and removal can be an indicator of disease or 
dysfunction [131]. Accumulation of lipids, which form droplets in the liver, is 
called hepatic steatosis. Chances of developing hepatic steatosis increase with 
age [132]. Hepatic lipid accumulation has been linked to insulin resistance [133]. 
Hepatic steatosis can progress into more serious diseases including non-
alcoholic fatty liver disease or non-alcoholic steatohepatitis. 
 
 
2.6 Positron Emission Tomography  
2.6.1 Principle of PET imaging   
PET is an imaging modality that detects the emission of high-energy 
photons emitted from radiotracers. PET has a purpose in both research and 
clinical settings. It begins with a proton-rich isotope that decays to a neutron, a 
positron and a neutrino. The positron emitted travels a short distance through 
tissues before it reaches an electron in the tissue. The particles combine and 
“annihilate” each other resulting in the emission of two coincidence gamma ray 
photons (Figure 4). Each of the resulting photons has an energy of 511keV. 
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Detectors are usually arranged in a ring to simultaneously detect the two gamma 





Figure 5. A representation of the principle of PET imaging. The radiotracer 
isotope decays releasing a neutron, a positron (b+), and a neutrino (n). The 
positron collides with an electron in the tissue and they annihilate producing two 
gamma ray photons that can be read by a ring of detectors. Image adapted from 
Miller et al. 2008 [134].  
 
2.6.2 PET Radiotracer – 18F-FDG  
18F-FDG is commonly used in animal research and clinical settings to 
assess tissue specific glucose metabolism. 18F-FDG possesses several ideal 
characteristics for a radiotracer including a short positron range and half-life of 
109.8 minutes allowing sufficient time to image, but is not long enough to 
cause prolonged radiation exposure. 18F is a proton rich isotope that replaces a 
hydroxyl group at position C-2 on a deoxyglucose molecule. Deoxyglucose is a 
glucose analogue that can be taken up by glucose transporters. Therefore, 18F-




















cell, 18F-FDG is phosphorylated by hexokinase to FDG-6-phosphate. The 
phosphorylated metabolite is no longer a substrate for GLUT1 or 4, cannot be 
metabolized further, and accumulates in the cell. In the presence of glucose-6-
phosphatase, FDG-6-phosphate can be dephosphorylated and leave the cell 
but this happens slowly as the amount of glucose-6-phosphatase is limited. 
The liver is one exception; it has more glucose 6-phosphatase than other tissues 
allowing the tracer to evacuate the cells and prevents accumulation of the tracer 
[135]. The amount of tracer present in a tissue is proportional to glucose uptake. 
Metabolically active tissues will take up glucose. 18F-FDG was originally used in 
oncology for the identification of cancer cells which have increased glucose 
metabolism as reviewed in an article by Almuhaideb et al. 2011 [136]. It can also 
be used to measure physiological glucose uptake or response to treatment in the 
heart, brain, BAT, muscle, bladder, liver and kidneys and allow for visualization of 
interaction between the organs.  
 
2.6.3 18F-FDG PET for Tissue Specific Glucose Uptake in IBAT 
PET imaging with 18F-FDG was pivotal in the discovery of BAT in 
humans. Now, 18F-FDG uptake is used to measure metabolic activity. Initially, it 
was commonly used to indirectly measure thermogenesis but recent findings 
suggest that the stimulation of b-adrenergic signaling can increase 18F-FDG 
uptake independent of UCP1 thermogenesis [56], [137], [138]. In one 
contradictory study, female UCP1 knock-out mice were used in an experiment 
with b-adrenergic agonist, CL316243, that observed 18F-FDG uptake to be 
unaffected when compared to wild-type mice [56]. On the other hand, in male 
UCP1 knock-out mice, b-adrenergic stimulated activation was dependent on 
the presence of UCP1 [139].  
Other factors that affect 18F-FDG uptake in human BAT are sex, age, 
BMI, and environmental temperature. Regions of active BAT marked by 18F-
FDG uptake are more prevalent in females than males [10]. 18F-FDG uptake in 
BAT is also dependent on age where younger individuals demonstrate higher 
uptake than older individuals [140]. Lower outdoor temperatures, measured 
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monthly, increased BAT glucose uptake [140]. 18F-FDG has an inverse 
relationship to BMI [141]. The final factor that can affect 18F-FDG uptake in 
BAT is insulin sensitivity. Cold-stimulated glucose uptake in BAT is reduced in 
insulin-resistant states like diabetes [142]. More information is needed to find 
out if diabetes is responsible for the decrease in BAT glucose uptake or the 





Chapter 3: Methodology and Experimental Design  
3.1 Institutional Animal Care Approval 
C57Bl/6J wildtype offspring mice received from McMaster University, 
breeders originally from the Jackson Laboratory (Bar Harbor, Maine, USA), were 
acclimatized for one week after arrival to Thunder Bay. They were housed in 
Allentown individually ventilated cages with between 2-4 mice of the same sex 
per cage. The cages were placed on Innovive Innorackâ IVC mouse racks. 
Housing temperature was controlled, at 22°C ± 3°C. Each cage had a plastic 
enrichment dome. Mice were kept on a 12-hour light/dark cycle. Mice had 
unlimited access to food and water. Food was ProlabÒ RMH 3000.  
Institutional animal care approval was received from Lakehead University 




3.2 Experimental Design  
3.2.1 Breeding  
Male and female C57Bl/6J wildtype mice, age 7-8 weeks, were given one 
week to acclimate without disruption. Females were housed 5 per cage from 
arrival until breeding. Males were individually housed for the duration of the 
study. Animals had unlimited access to food and water and a 12-hour light/dark 
cycle was maintained. Female mice were moved to a male cage (2 females:1 
male) and allowed to breed overnight. The following morning, females were 
removed from the male cages and individually housed. Vaginal plugs were used 
to determine the first day of gestation. Prior to irradiation, animals were palpated 
to confirm pregnancy and only pregnant mice were irradiated as described in 
section 3.2.2. Animals were transported to a different building for radiation 
treatment. Following irradiation, the mice were returned to the housing room and 
remained individually housed. Mothers were left uninterrupted for a minimum of 
one week following birth (including cage changes). Pups were weaned at 3-4 
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weeks of age and sex was determined. They were then housed up to 3 males or 
4 female F1 pups in a cage. A maximum of two pups from a single mother was 
used in this study to control maternal effects.  
 
3.2.2 Treatments  
Radiation treatments were done at McMaster University. Pregnant 
females were exposed to ionizing radiation a single time at 1000 mGy on day 15 
of gestation using 137Cs gamma radiation (662 keV energy) (Taylor Radiobiology 
Source). The mice were transported in a temperature controlled vehicle to the 
Taylor Source irradiation facility. Following transportation, mice were placed 
under the source for 20 minutes prior to irradiation in their home cage. Sham-
irradiated animals were placed under the shielded source for 20 minutes and 
were then moved to the control room for the duration of the irradiation. Access to 
food and water were restricted for the period of irradiation (sham-irradiated 
animals included). Radiation was delivered at a dose rate of 10 mGy/min 
measured using thermoluminescent dosimeters (Mirion Technologies, Irvine, 
California, USA) placed in the bedding of an empty animal cage with the lid on. 
The cages were transported back to the animal housing facility. The mice were 
shipped to Thunder Bay at 3 ½ months of age. Once at the Thunder Bay animal 
facility, the mice were left to acclimate for one week. Experiments commenced 
when the offspring reached 4 months ± one week of age.  
 
3.2.3 Image Acquisition  
To assess glucose uptake in interscapular brown adipose tissue (IBAT), 
18F-fluorodeoxyglucose (FDG) was obtained from the cyclotron (Thunder Bay 
Regional Health Research Institute, Thunder Bay, ON, Canada) on experiment 
days. A concentration of approximately 300 µCi/ml diluted with sterile saline was 
made following the FDG Dilution Worksheet (Appendix). A mouse was 
anesthetized with 1.5% isoflurane anesthetic for five minutes inside a vapour 
induction chamber. An intraperitoneal injection of the appropriate volume at a 
dose of approximately 20 µCi was given. There was a wait time of 15 minutes 
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between injections of each subsequent mouse to avoid scan time overlap. After 
55 minutes, the mouse was anesthetized with 1.5% isoflurane for five minutes. 
The mouse was then placed in the imaging chamber in a prone position and 
inserted into the G4 PET/X-ray scanner (Sofie Biosciences, Culver City, 
California, USA). The imaging chamber contains a nose cone for isoflurane 
administration at 1.5% during the scan to maintain lack of consciousness. The 
base of the imaging chamber was heated to 37°C to maintain their core body 
temperature. A 10-minute acquisition was performed followed by an X-ray. Each 
mouse was subsequently imaged under the same parameters. After 
experimentation, mice were placed back in their original cages to recover with 
access to food and water.  
 
3.2.4 Image Analysis  
Glucose uptake was measured using 18F-FDG radiotracer and microPET 
imaging. VivoQuantä(Version 1.23, Invicro, Boston) image analysis software was 
used to reconstruct and quantify glucose uptake in IBAT. A region of interest was 
selected to encompass the tissue. A draw tool was used to account for the 
volume of the entire tissue. From the encompassed tissue, maximum 
standardized uptake value (SUVMAX) was calculated and reported in SUV/mm3. 








3.2.5 Tissue Collection  
One week after image acquisition, mice were anesthetized under 3% 
isoflurane anesthetic and the hearts removed. IBAT, livers, and hearts were 
immediately frozen on dry ice for future analysis. Blood was collected from the 
chest cavity and stored in tubes containing EDTA on ice for plasma isolation. 
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Within two hours, the blood was centrifuged at 3000 g for 10 minutes at 4°C. The 
supernatant (plasma) was collected and stored at -30°C until analysis.  
 
3.2.6 Tissue Lysis   
Frozen liver tissue was pulverized into powder using a mortar and pestle 
kept cold with liquid nitrogen and kept on dry ice. The powder was stored at -
80°C until analysis. 
For western blots, frozen liver powder was disrupted and homogenized in 
ice-cold lysis buffer (25mmol/L Tris pH = 7.5, 150 mmol/L NaCl, 1 mmol/L EDTA, 
1% Triton-X 100) with an addition of sodium fluoride (NaF) (Sigma Life Science, 
St. Louis, Missouri, USA), sodium orthovanadate (Na3VO4) (Sigma Life Science, 
St. Louis, Missouri, USA) and protease inhibitor cocktail (Sigma Life Science, St. 
Louis, Missouri, USA). Disruption and homogenization was completed using the 
Qiagen TissueLyser. Samples were centrifuged at 16000 g for 10 minutes at 4°C 
and supernatants were collected. 1:20 dilutions were made for the protein assay 
and the rest of the sample stored at -80°C until further analysis could be 
completed.  
For western blots, frozen IBAT (whole) was disrupted and homogenized in 
ice-cold lysis buffer (25mmol/L Tris pH = 7.5, 150 mmol/L NaCl, 1 mmol/L EDTA, 
1% Triton-X 100) with an addition of sodium fluoride (NaF) (Sigma Life Science, 
St. Louis, Missouri, U.S.A.) and protease inhibitor cocktail (Sigma Life Science, 
St. Louis, Missouri, U.S.A.). Disruption and homogenization was completed using 
the Qiagen TissueLyser. Samples were centrifuged at 16000 g for 10 minutes at 
4°C, and the intermediate layer collected. The supernatant was centrifuged a 
second time and the intermediate layer collected. Prepared samples were stored 
at -80°C until further analysis could be completed. Protein assays were 
completed (PierceÔ BCA Protein Assay Kit, Thermo Scientific, Rockford, Illinois, 
U.S.A.) to determine protein content for western blot analysis. 1:4 dilutions were 




3.2.7 Protein Assay  
Prior to performing western blots, protein assays were completed to 
determine protein content for western blot analysis and for sample normalization. 
Protein assays were completed as per Pierceä BCA Protein Assay Kit. Protein 
assays were performed the same day as tissue lysis to avoid the freeze-thaw 
cycle. Steps were followed as per Pierceä BCA Protein Assay Kit: Samples and 
bovine serum albumin standards (10µl) were loaded into a Costar 96 flat bottom 
plate (9017) in duplicate. Once all samples were loaded, 200µl of working 
reagent (prepared 50:1 for reagent A:B) was added to each well containing 
standard or sample. The plate was mixed on the plate shaker at 200rpm for 30 
seconds. After mixing, the plate was incubated at 37°C for 30 minutes. After 
incubation, the plate was cooled to room temperature and read at 562nm on a 
BioTek Power Wave XS microplate reader using Gen5 data analysis software.   
 
3.2.8 Sample Preparation for Western Blot  
 After the protein assay was performed, the liver and IBAT samples were 
prepared for western blots. Samples were kept on ice for the duration of the 
preparation. A 1ml aliquot of sample reducing buffer (4X Laemmli buffer) was 
thawed at room temperature. Once thawed, 110µl of 100mM dithiothreitol (DTT) 
(Fisher Scientific, Fair Lawn, NJ, cat# BP172-25) was added to the sample 
reducing buffer. Using a needle, a set of 1.5ml tubes had a hole poked in each 
lid. Distilled water was added to each tube. 1.5µg/µl of sample was added to its 
corresponding 1.5ml tube. The appropriate volume of sample reducing buffer 
was added to each tube. The tubes were boiled at 100°C for 5 minutes. Western 
blot prepared samples were placed back on ice to cool. Western blot prepared 
samples and original samples were stored in at -80°C until western blots could 
be performed.  
 
3.2.9 Western Blotting 
(see Appendix for full Lees Lab Western Blot SOP) 
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Polyacrylamide gels were prepared at a 15% concentration for SOCS3 
isolation and 10% concentration for PEPCK, UCP1, phosphorylated Akt (pAkt), 
Akt, phosphorylated GSK3b (pGSK3b), and GSK3b isolation. Samples prepared 
in section 2.3.7 were thawed on ice. 5µl of molecular ladder (BLUelf prestained 
protein ladder, FroggaBio, Canada, cat #PM008-500) was added to the first well. 
Samples were loaded alternating treatment groups. Several samples were 
repeated across gels as loading controls. All gels were run for 1 hour at 200 
volts. Each gel was transferred to a nitrocellulose membrane. Ponceau S staining 
was used as a marker of equal protein loading. Ponceau S stains were quantified 
using ImageJ. The same four band region on each lane was selected 
encompassing the area where the target protein would be located based on 
molecular weight. Ponceau S staining was chosen instead of other loading 
controls because standard housekeeping proteins (e.g., GAPDH and b-actin) can 
be affected by different cellular process and may not accurately reflect total 
protein loads [143]. The blocking solution consisted of 5% powdered milk in 
1XTBST (TBST: Tris Base, Molecular Biology Grade, Fisher Scientific, Fair 
Lawn, NJ, cat # BP152-5 + Tris Hydrochloride, Fisher Scientific, Fair Lawn, NJ, 
cat # BP153-500 + Tween 20, Bio Rad, Hercules, CA, USA, cat # 1706531). 
Immunoblotting was performed using the primary antibody: SOCS3 (Cell 
Signaling Technology, Danvers, MA, cat #2923), anti-PCK1 (Abcam, Cambridge, 
MA, cat # ab70358), UCP1 (D9D6X) Rabbit mAb (Cell Signaling Technology, 
14670, Danvers, MA, USA), Phospho-Akt (Ser473)(D9E) XPâ Rabbit mAb (Cell 
Signaling Technology, 4060, Danvers, MA, USA), Akt (pan) (C67E7) (Cell 
Signaling Technology, 4691, Danvers, MA, USA), Phospho-GSK-3b (Ser9) (Cell 
Signaling Technology, 5558, Danvers, MA, USA) or GSK-3b XPâ Rabbit mAb 
(Cell Signaling Technology, 12456, Danvers, MA, USA). After incubation, the 
secondary antibody Pierce antibody goat-anti rabbit IgG (H + L) (Thermo 
Scientific Pierce, Rockford, IL, cat# 31460) were used for all blots. SuperSignalä 
West Pico Chemiluminescent Substrate was used for SOCS3 and pAkt. For all 
other targets, immunoreactive complexes were detected with enhanced 
chemiluminescence (ChemiDocä XRS, Bio-Rad, Hercules, CA, USA). All blots 
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were quantified using ImageJ software. Loading controls were used for 
normalization.  
 
3.2.10 Triglyceride Assay  
Powdered liver samples were removed from the -80°C freezer and placed 
on dry ice. Frozen liver powder was weighed out and homogenized in ice-cold 
lysis buffer (5% Igepal CA-630, MP Biomedicals, Solon, OH, cat # 19859650) 
with addition of Protease Inhibitor Cocktail (Sigma Life Science, St. Louis, 
Missouri, USA). Homogenization was completed using the Qiagen Tissue Lyser. 
Samples were then centrifuged at 16000 g for 10 minutes at 4°C, supernatants 
were collected and a protein assay performed to avoid the freeze-thaw cycle of 
the sample. Protein assays were completed (Pierceä BCA Protein Assay Kit, 
Thermo Scientific, Rockford, Illinois, USA) as per section 2.3.6 to determine 
protein content for normalization. Plasma samples were removed from the -30°C 
freezer and placed on ice to thaw.  
Triglyceride assays were completed to determine hepatic and plasma 
triglyceride content (Triglyceride Colorimetric Assay Kit, Cayman Chemical 
Company, Ann Harbor, Michigan, USA). NP-40 from the kit was replaced with, a 
chemically indistinguishable substitute, 5% Igepal CA-630 (MP Biomedicals, 
Solon, OH, cat # 19859650). Samples (10µl) were loaded into a Costar 96 flat 
bottom plate (9017) in duplicate. Once all samples were loaded, 150µl of Enzyme 
Buffer was added to each well containing sample. The plate was mixed on the 
plate shaker at 200rpm for 30 seconds. After mixing, the plate was incubated at 
room temperature for 15 minutes. After incubation, the plate was read at 540nm 
on a BioTek Power Wave XS microplate reader (model #MQX200R) using Gen5 




3.3 Limitations, Basic Assumptions, and Delimitations 
3.3.1 Limitations and Basic Assumptions  
This study could not be performed on humans and therefore, a mouse 
model was adopted to study the effects of radiation. Animal models often 
represent physiological treatments better than cell culture models. In this study 
animals were used for all experiments. Based on our regular monitoring of the 
animals it is assumed that all mice consumed a similar amount of food and water 
and remained well-fed and hydrated. This strain of mouse is thought to represent 
healthy normal physiological conditions and assumed to be pathogen and 
disease free. 
Other limitations are environmental factors that unknowingly affect the 
animals including transportation and disruption of light/dark cycles. All mice are 
kept in the same environment but may be exposed to stressors that may cause 
uncontrollable variation in results. The mice were transported to and from the 
irradiation facility at McMaster University 2-3 times a week starting one week 
prior to breeding and between gestational days 8 and 15 to minimize stress at 
the time of irradiation. Transport from Hamilton, Ontario to Thunder Bay, Ontario 
may have presented an additional stressor. While transportation acclimation was 
done for road transportation in the parents, the offspring were never mock 
transported. The offspring were flown to Thunder Bay introducing another stress 
event. While air travel is the main route of transport from the facility where the 
mice are born to a research facility, offspring that have been exposed to 1000 
mGy in-utero may respond differently to the stress and have an adverse 
response to flying. The effects and extent of variations and how they relate to this 
study are unknown.  
 
3.3.2 Delimitations  
Mice are more radioresistant than humans and required a higher whole-
body dose of radiation to illicit similar effects. 1000 mGy of whole-body irradiation 
is assumed to be similar to a low dose exposure in humans. One potential 
limitation of this study is the strain of mice used. C57Bl/6J mice were used 
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exclusively. Research regarding the potential radioresistance of C57Bl/6 mice 
has emerged suggesting that other strains of mice may be more sensitive to 
radiation. Using other strains of mice such as BALB/C, may show more 
significant changes in offspring related to fetal programming when the dam is 
exposed to the same dose of radiation. Increasing the radiation dose to produce 
similar effects in C57Bl/6 mice was chosen over selecting another strain so that 
comparisons to other models of fetal programming, which commonly use C57Bl 
mice, could be made. A second reason for choosing C57Bl/6J mice was for 
future comparison to dexamethasone studies. The final reason for choosing 
C57Bl/6J mice was the availability of knockout models for comparison in future 
studies.  
Image analysis was done by the same individual to maintain consistency 
and limit variation as personal judgement is required when using the analysis 
software. Using the same individual does not allow for comparison to account for 
bias or skew, but for consistency one person is used for all image analysis.  
3.4 Statistical Analysis  
All data was presented as means ± SEM. Comparisons between 
treatment groups was done using two-tailed Student’s t-tests. A resulting p-value 






Chapter 4. Results 
4.1 Anthropometric Results   
4.1.1 SLDR Exposure Did Not Alter Body Weight at 4 Months of Age 
A key indicator of fetal programming is low birth weight. Birth weights were 
not recorded to reduce stress from handling and filial cannibalism. At 4 months of 
age, female offspring body weight decreased with treatment but the change was 
not significant (p = 0.07) (Figure 6). There was no change in body weight in the 
male offspring caused by maternal exposure to 1000 mGy (p =0.92) (Figure 6). It 
is possible that catch-up growth occurred and any differences that may have 
existed previously are no longer visible.  
 
Figure 6. Body weights. There were no differences in body weight between the 
treatments when measured at 4 months of age. Data are presented as mean ± 
SEM. n = 7-10 per group.  
  
4.1.2 SLDR Exposure Altered Female Liver Weight and Male Heart Weight 
Tissue weights were collected for heart, liver, and IBAT (Table 3). Tissue 
weights were compared to body weight for each mouse to determine if there was 
any difference in tissue weight between treatment groups. Heart weight to body 
weight ratio decreased in the male offspring of irradiated dams (p = 0.01) (Figure 
7A). Female heart weight to body weight ratio was unchanged (p = 0.81). There 
was no difference in the IBAT to body weight ratio in females (p = 0.36) or males 



















female offspring from irradiated dams (p = 0.05) but did not change significantly 
in the males (p = 0.46) (Figure 7C).  
 
Table 3. Tissue weights from offspring of irradiated and sham irradiated dams. 
 Male Female 
 Sham 1000mGy Sham 1000mGy 
Body Weight 
(g) 
27.80 ± 1.11 27.66 ± 0.87 
 
21.14 ± 0.58 
 
















121.27 ± 7.20 103.15 ± 2.10* 
 
87.31 ± 2.52 
 




86.51 ± 8.24 
 
80.09 ± 4.49 
 
50.13 ± 2.53 
 
46.93 ± 2.24 
 
Measurements were taken at 4 months of age. Tissue weights were taken prior 
to freezing. Data are presented as means ± SEM. *Significant differences (p £ 

























Figure 7. Tissue to body weights. Measured one week after microPET imaging. 
Black bars represent female tissue weight. White bars represent male tissue 
weight. *Significant differences (p £ 0.05) between treatment groups. Data are 







































































4.2 Proteins Involved in Glucose Metabolism in the Liver  
4.2.1 Increased Hepatic SOCS3 in Female Offspring 
The female offspring of irradiated dams had significantly increased 
SOCS3 protein expression by 20% compared to offspring from sham irradiated 
dams (p = 0.03) (Figure 8A). There was a 27% difference in SOCS3 protein 
expression between male sham and male 1000 mGy treatment groups but it was 
not significant (p = 0.07) (Figure 8B). Unexpectedly, there was a trend towards 
the opposite effect as the females, where males from irradiated dams had lower 
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Figure 8. Liver SOCS3 protein expression from offspring of irradiated and sham 
irradiated dams at 4 months of age. (A) Representative western blot of SOCS3 in 
female mice. Black bar represents SOCS3 protein expression in the liver of sham 
irradiated female offspring. Grey bar represents SOCS3 protein expression in the 
liver of female offspring from irradiated dams. (B) Representative western blot of 
SOCS3 in male mice. Black bar represents SOCS3 protein expression in the liver 
of sham irradiated male offspring. Grey bar represents SOCS3 protein 
expression in the liver of male offspring from dams irradiated at 1000 mGy. 
Results were normalized to loading controls. Ponceau S stains are shown as 
markers of equal protein loading. *Significant differences (p £ 0.05) between 






































4.2.2 Increased Hepatic PEPCK in Female Offspring 
The female offspring of irradiated dams had significantly increased (15%) 
protein expression of PEPCK in the liver compared to the offspring of sham 
irradiated dams (p = 0.002) (Figure 9A). There was an 12% decrease in PEPCK 
protein expression between male sham and male 1000 mGy treatment groups 


























































Figure 9. Liver PEPCK protein expression from offspring of irradiated and sham 
irradiated dams at 4 months of age. (A) Representative western blot of PEPCK in 
female mice. Black bar represents PEPCK protein expression in the liver of sham 
irradiated female offspring. Grey bar represents PEPCK protein expression in the 
liver of female offspring from irradiated dams. (B) Representative western blot of 
PEPCK in male mice. Black bar represents PEPCK protein expression in the liver 
of sham irradiated male offspring. Grey bar represents PEPCK protein 
expression in the liver of male offspring from irradiated dams. Results were 
normalized to loading controls. Ponceau S stains are shown as markers of equal 
protein loading. *Significant differences (p £ 0.05) between treatment groups. 



































4.3 Hepatic and Plasma Triglyceride Content  
A triglyceride assay was performed on liver tissue dissected from the mice 
at 4 months of age. No difference was observed in hepatic triglyceride content in 
the females based on treatment (p = 0.45) (Figure 10A). However, in the male 
offspring, the 1000 mGy treatment group has higher hepatic triglyceride content 
than the sham group (p= 0.02) (Figure 10B). Female plasma triglyceride 
concentration increased by 28% with treatment but the change was not 
significant (p = 0.08) (Figure 11A). No differences were observed from treatment 









































Figure 10. Triglyceride content in the liver. (A) Female hepatic triglyceride 
content. Black bar represents hepatic triglyceride content in female sham 
irradiated offspring. Grey bar represents hepatic triglyceride content in female 
offspring of irradiated dams. (B) Male hepatic triglyceride content. Black bar 
represents hepatic triglyceride content in male sham irradiated offspring. Grey 
bar represents hepatic triglyceride content in male offspring of irradiated dams. 
Triglyceride content was normalized to liver protein content. *Significant 
differences (p £ 0.05) between treatment groups. Data are presented as mean ± 























































    
Figure 11. Plasma triglyceride concentration. (A) Female plasma triglyceride 
concentration. Black bar represents plasma triglyceride concentration in female 
sham irradiated offspring. Grey bar represents plasma triglyceride concentration 
in female offspring of irradiated dams. (B) Male plasma triglyceride concentration. 
Black bar represents plasma triglyceride concentration in male sham irradiated 
offspring. Grey bar represents plasma triglyceride concentration in male offspring 
of irradiated dams. *Significant differences (p £ 0.05) between treatment groups. 












































4.5 Glucose Uptake Increased in Female Offspring IBAT  
Tissue specific glucose uptake was measured in vivo with a 10-minute 
static PET scan with 18F-FDG. Glucose uptake increased by 36% in female 
offspring of dams irradiated at 1000 mGy compared to female sham offspring (p 
= 0.003) (Figure 12). There was no significant change with treatment in the male 
offspring (p = 0.35). Changes in uptake are presented as SUVMAX. 
 
 
Figure 12. 18F-FDG uptake. Black bars represent female IBAT 18F-FDG uptake. 
White bars represent male IBAT 18F-FDG uptake. *Significant differences (p £ 
0.05) between treatment groups. Data are presented as mean ± SEM. n = 7-10 






























4.6 IBAT Signaling  
4.6.1 No Detectable Changes in Akt Protein Expression or Phosphorylation 
The phosphorylation and expression of Akt, a signaling protein associated 
with insulin signaling was measured in IBAT. In female offspring, treatment did 
not result in significant changes in phosphorylated Akt Ser473 (pAkt) (p = 0.99) 
or total Akt (p = 0.70) (Figure 13B). When presented as a ratio of pAkt to total 
Akt, there remain no difference in the females (p = 0.79) (Figure 13C). In male 
offspring, there are no significant changes in pAkt (p = 0.80) or total Akt (p = 
0.60) (Figure 14B). Figure 14C shows the ratio of pAkt to total Akt in male 




























Figure 13. Female phosphorylated Akt (Ser473) (pAkt) and total Akt protein 
expression. (A) Representative western blots for pAkt and total Akt in IBAT from 
female offspring of sham and irradiated dams. Ponceau S stains are shown as 
markers of equal protein loading. (B) Black bars represent pAkt protein 
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represents ratio of pAkt to total Akt protein expression in female offspring of 
sham irradiated dams. Grey bar represents ratio of pAkt to total Akt protein 
expression in female offspring of dams irradiated at 1000 mGy. Results were 

































Figure 14. Male phosphorylated Akt Ser473 (pAkt) and total Akt protein 
expression. (A) Representative western blots for pAkt and total Akt in IBAT from 
male offspring of sham and irradiated dams. Ponceau S stains are shown as 
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expression. White bars represent total Akt protein expression. (C) Black bar 
represents ratio of pAkt to total Akt protein expression in male offspring of sham 
irradiated dams. Grey bar represents ratio of pAkt to total Akt protein expression 
in male offspring of dams irradiated at 1000 mGy. Results were normalized to 
loading controls. Data are presented as mean ± SEM. n = 7-10.  
 
4.6.2 Non-significant Increase in Phosphorylated GSK3b  
The phosphorylation and expression of GSK3b, a signaling protein 
associated with b-adrenergic signaling was measured in IBAT. There was no 
difference in total GSK3b protein expression in the female offspring with 
treatment (p = 0.43) and phosphorylated GSK3b Ser9 (pGSK3b) protein 
expression increased by 41% but the change was not significant because of the 
variability between samples (p = 0.27) (Figure 15B). There was no change 
observed in the ratio of pGSK3b to total GSK3b in females with treatment when 
compared to sham irradiated (p = 0.82) (Figure 15C). In the males, there were 
non-significant increases of 14% in total GSK3b protein expression (p = 0.31) 
and 36% in pGSK3b protein expression (p = 0.22) (Figure 16B). The ratio of 






















Figure 15. Phosphorylated GSK3b Ser9 (pGSK3b) and total GSK3b protein 
expression. (A) Representative western blots for pGSK3b and total GSK3b in 
IBAT from female offspring of sham and irradiated dams. Ponceau S stains are 
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protein expression. White bars represent total GSK3b protein expression. (C) 
Black bar represents ratio of pGSK3b to total GSK3b protein expression in 
female offspring of sham irradiated dams. Grey bar represents ratio of ratio of 
pGSK3b to total GSK3b in female offspring of dams irradiated at 1000 mGy. 
Results were normalized to loading controls. Data are presented as mean ± 



































Figure 16. Phosphorylated GSK3b Ser9 (pGSK3b) and total GSK3b protein 
expression. (A) Representative western blots for pGSK3b and total GSK3b in 
IBAT from male offspring of sham and irradiated dams. Ponceau S stains are 
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protein expression. White bars represent total GSK3b protein expression. (C) 
Black bar represents ratio of pGSK3b to total GSK3b protein expression in male 
offspring of sham irradiated dams. Grey bar represents ratio of ratio of pGSK3b 
to total GSK3b in male offspring of dams irradiated at 1000 mGy. Results were 
normalized to loading controls. Data are presented as mean ± SEM. n = 7-10.  
      
4.6.3 UCP1 Protein Expression Did Not Significantly Change 
The presence of UCP1 can clarify that the tissue being tested is brown 
adipose tissue as opposed to white adipose tissue. It is also used as a marker of 
thermogenesis and is activated by b-adrenergic signaling. UCP1 protein 
expression changed between treatments by 9% in the females but was not 
significant (p = 0.07) (Figure 17A). There was no significant change in males (p = 










































Figure 17. UCP1 protein expression from offspring of irradiated and sham 
irradiated dams at 4 months of age. (A) Representative western blot of UCP1 in 
IBAT of female mice. Black bar represents UCP1 protein expression in the liver 
of sham irradiated female offspring. Grey bar represents UCP1 protein 
expression in female offspring from irradiated dams. (B) Representative western 
blot of UCP1 in IBAT of male mice. Black bar represents UCP1 protein 
expression of sham irradiated male offspring. Grey bar represents UCP1 protein 
expression in male offspring from irradiated dams. Results were normalized to 
loading controls. Ponceau S stains are shown as markers of equal protein 
loading. *Significant differences (p £ 0.05) between treatment groups. Data are 




































Chapter 5. Discussion  
This study examined the effects of sub-lethal radiation on glucose 
metabolism of mice. The assumption is that radiation is dangerous and concerns 
arise in the workplace and among the general public. While radiation protection 
regulations and standards are in place to prevent repeated and prolonged 
exposure, there are concerns about low dose exposures in humans. Even less is 
known about the effects of LDR when exposed in-utero. Radiation exposure 
during pregnancy presents a stress event that has the potential to permanently 
alter fetal metabolic processes. The effects may not be observable at birth or in 
early life but adult disease may arise at a younger age than expected. To 
investigate alterations in physiology and metabolism, a mouse model using sub-
lethal dose radiation was used. The outcomes can be helpful in estimating the 
effects of LDR on fetal programming in humans. Based on the results from liver 
protein expression of targets associated with insulin resistance and alterations in 
IBAT glucose uptake, fetal programming can be caused by a sub-lethal dose of 
radiation in mice.   
 
 
5.1 Birth Weight and Catch-up Growth  
While it was expected that offspring born to irradiated dams would 
exhibit low birth weights (LBW) similar to other models of fetal programming, 
birth weights were not recorded to minimize handling stress and cannibalism. 
LBW is associated with long-term metabolic consequences in humans 
including impaired glucose tolerance, type 2 diabetes, hypertension and 
cardiovascular disease [40], [144]. LBW could have provided insight to the 
early effects of radiation on the fetus. For example, if the level of stress 
hormones crossing the placenta increased affecting the fetal HPA axis or if the 
stress from radiation altered the metabolism of the mother limiting the 
necessary nutrients from reaching the fetus. Although no change was 
observed in body weight (Figure 6), this may be the result of postnatal catch-up 
growth. Catch-up growth is a type of compensation where growth is 
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accelerated until a normal height or weight for age is reached [145]. It is 
common after a period of slow or impaired growth like IUGR from maternal low 
protein diet [146]. Catch-up growth has been shown to be important in the 
programming of metabolic disease risk [147]–[149]. While we have no 
evidence that offspring were born at LBW or catch-up occurred, it would 
explain the alterations observed in liver glucose metabolism.  
 
 
5.2 Tissue Weight and Disease Development  
Previously, decreased heart weight has been observed in a model of fetal 
programming from low protein diets using rats but there were no differences in 
the heart weight to body weight ratio [150]. The decrease observed between the 
heart to body weight ratio in male mice from the present study (Figure 7A) could 
be the result of a species difference between rats and mice or a sex difference 
that wasn’t noticed in the previously mentioned study because the measures for 
the sexes were combined [151]. Increased liver weight, as seen in the female 
offspring of irradiated dams (Figure 7C), could indicate triglyceride or lipid build 
up in the liver called hepatic steatosis which is an indicator of pathophysiology 
like non-alcoholic fatty liver disease (NAFLD) [151]. NAFLD is likely to develop as 
a result of obesity or high fat diet and is linked to other metabolic alterations like 
insulin resistance [151], [152]. The chow used was standard and not high in fat 
so it was unexpected to observe increased liver weight. However, the mice had 
unlimited access to food and water and didn’t record food consumption. There 
were no visibly obese mice that would lead us to believe that overfeeding would 
be responsible for increased liver weight in the absence of obesity. 
Unexpectedly, the male offspring of irradiated dams had increased hepatic 
triglycerides and the females did not (Figure 10). Increased hepatic triglycerides 
are usually seen in advanced disease like NAFLD, but this was not a model of a 
diseased state. Further studies could be done to look at gene expression of 
genes involved in lipid metabolism in sham mice compared to mice irradiated in-
utero at 1000 mGy to look for differences between male and female offspring. 
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Radiation is known to damage the liver and can induce liver disease and 
cirrhosis but here there is no evidence of direct liver damage to the fetus when 
the mother is exposed to whole-body radiation therefore, fetal programming is 
likely responsible for the increased liver weight in females and increased hepatic 
triglyceride content in the male offspring.  
 
5.3 Metabolic Alterations in the Liver  
 The increased liver weight in female offspring led us to continue to 
examine the liver for signs of metabolic alterations. Targets of insulin resistance 
were measured in both sexes using protein expression from western blots. First 
was SOCS3, a known modulator of insulin resistance in the liver [153]. SOCS3 is 
a protein induced by proinflammatory cytokines that directly inhibits IRS1/IRS2 
by binding to specific sites, inhibiting phosphorylation and targeting the receptor 
substrates for degradation (Figure 18) [154]. In turn, this causes decreased 
activity in downstream components of the insulin signaling pathway. Therefore, 
SOCS3 is important in mediating insulin stimulated glucose uptake. Insulin 
resistance is a common consequence of exposure to stress, where stress results 
in the activation of proinflammatory cytokines that will upregulate SOCS3 [155]. 
In models of insulin resistance, SOCS3 protein expression is elevated in the liver 
[154], [156]. From our results, female SOCS3 expression increased in offspring 
of dams that were exposed to 1000 mGy of radiation (Figure 8A) suggesting the 






Figure 18. SOCS3 signaling. Increased SOCS3 negatively regulates insulin 
signaling by inhibiting insulin receptor substrate (IRS-1/IRS-2) phosphorylation 
and marking them as targets for degradation. This decreases activity 
downstream of the receptor substrates and reduces GLUT4 mediated glucose 
uptake into skeletal muscle. Less is known about the mechanism of SOCS3 in 
the liver but it is known to act on IRS1/IRS2 mediating glucose uptake into the 
liver. Adapted from Sarvas et al. 2013 [153]. 
 
Alone, SOCS3 is not enough to indicate insulin resistance. PEPCK was 
used as a second indicator of insulin resistance in the liver. PEPCK is a rate-
limiting enzyme that catalyzes the first step in gluconeogenesis, the conversion 
of oxaloacetate to phosphoenolpyruvate, and links glucose metabolism to the 
citric acid cycle (Figure 19) [157]. In the liver, insulin signaling regulates 
gluconeogenesis by inhibiting key enzymes like PEPCK resulting in reduced 
hepatic glucose output. PEPCK is important in maintaining normal blood 
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glucose levels [158]. The activity of PEPCK is controlled by the rate of 
transcription of its gene by insulin, glucocorticoids and cAMP levels [159]. 
Overexpression of PEPCK leads to insulin resistance in the liver [160], [161]. 
The results of this study show increased PEPCK protein expression in females 
that were exposed to radiation in-utero (Figure 9A) which suggests insulin 
resistance. PEPCK increase also suggests gluconeogenesis would be 
increased in female offspring. With both targets of insulin sensitivity 
demonstrating increased expression, it can be concluded that female offspring 
of dams whole-body irradiated with 1000 mGy are more likely to be insulin 




Figure 19. PEPCK in hepatic gluconeogenesis. PEPCK is an enzyme that 
facilitates the conversion of oxaloacetate to phosphoenolpyruvate and links 
glucose metabolism to the citric acid cycle. PEPCK promotes the storage of 
glucose as glycogen to maintain normal blood glucose levels. Adapted from 















5.4 IBAT Glucose Uptake and Signaling  
Tissue specific glucose uptake was measured in IBAT with PET using 18F-
FDG. We report here that female offspring of irradiated dams have increased 18F-
FDG uptake in IBAT (Figure 12). This suggests they have hyperactive IBAT that 
uses more glucose and has increased energy expenditure compared to sham 
irradiated offspring. Since only activated BAT can be visualized, accumulation of 
18F-FDG indicates a high rate of glucose metabolism in the tissue. While there 
was no significant change in the weight of the tissue, IBAT 18F-FDG uptake may 
have increased to compensate for whole-body glucose intolerance. 
Compensation like this was observed in a study by Dumortier et al. 2017, in a 
fetal programming model of maternal low protein diet, where insulin secretion 
was impaired yet mice were able to maintain normal blood glucose levels and 
normal insulin sensitivity [26]. They observed increased energy expenditure by 
indirect calorimetry and hypothesized that increased IBAT uptake acts as a 
protection mechanism from changes in energy homeostasis and can protect 
against high-fat diet induced obesity. The protective effect was maintained in 
mice at 10 months of age but not at 18 months. With age, BAT activity declined 
and the mice were more susceptible to high-fat diet induced obesity and 
developed insulin resistance. This is an example of how age will affect the results 
of fetal programming studies and is an important factor in choosing a model for 
experiments. It is a possibility that if the mice from our study were tested at a 
later age, for example at 12 months, signs of insulin resistance in the liver would 
be increased and IBAT activity would deteriorate in comparison to what is seen 
at 4 months of age.  
To correlate with the increase in 18F-FDG uptake in females, it was 
hypothesized that plasma triglyceride concentration would decrease in the 
offspring from the treatment group. Decreased plasma triglycerides would 
indicate that BAT has increased activity and is using triglycerides for energy 
[162]. Unexpectedly, this was not the case. The opposite trend was observed 
where an increase in plasma triglycerides was seen in the females (p = 0.08) 
(Figure 11A). Increased levels of plasma triglycerides are an indicator of leptin 
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resistance [163]. Leptin is a hormone released by adipose tissue signaling 
starvation or hunger to the brain [164]. Leptin resistance means leptin levels in 
the body are high but the body itself does not require food and can lead to weight 
gain and obesity. Leptin levels were not measured in this study but could be a 
focus in the future to help explain the increased plasma triglycerides. Elevated 
plasma triglycerides are also a symptom of metabolic syndrome [40]. The 
compensation period may be ending in this cohort of mice and evidence of 
metabolic disease is becoming more obvious without the decrease in IBAT 
activity. The disappearance of increased IBAT activity as compensation for 
impaired glucose metabolism would not be expected until later in life.  
Phosphorylation of both Akt and GSK3b would have indicated that glucose 
uptake in IBAT is stimulated by insulin signaling [165] (Figure 4). However, there 
was no change in total Akt expression or more importantly phosphorylated Akt 
(Figure 13 & 14). The increase in phosphorylated GSK3b alone suggests the 
glucose uptake in female offspring IBAT is stimulated by b-adrenergic signaling 
(Figure 15). The phosphorylated form of these targets is more important because 
they will continue to move downstream in their pathways.  
The difficulty of IBAT tissue preparation made it hard to choose a target 
for b-adrenergic signaling. While there may exist a better target than GSK3b, the 
size of IBAT deterred us from cutting the tissue and the difficulty of breaking 
down the tissue led us to use only one method of preparation. This limited the 
type of tests we could run. Additionally, finding a different target for b-adrenergic 
signaling that doesn’t cross talk between pathways has yet to be established. In 
the future, a different tissue preparation method could be used to perform an 
enzyme-linked immunosorbent assay to measure cAMP as a target for b-
adrenergic signaling in IBAT.  
To corroborate the results of GSK3b expression, we looked at UCP1 
expression in IBAT. The presence of UCP1 in females and males from both 
treatment groups confirm that it is indeed BAT that we are testing since white 
adipose tissue does not contain this protein [108]. Additionally, the presence of 
UCP1 implies that the tissue is capable of thermogenesis. As mentioned 
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previously, UCP1 is activated through the b-adrenergic pathway (Figure 3). 
The increase in UCP1 expression in female offspring of irradiated dams 
(Figure17), while not significant (p = 0.07), in combination with the increase 
seen in phosphorylated GSK3b show a trend toward the b-adrenergic pathway 
being responsible for the increase in female IBAT uptake. This is not surprising 




5.5 Factors that Affect Fetal Programming 
The first factor that can affect the results of a fetal programming study is 
timing. The time point chosen for the stress event during pregnancy affects the 
severity and visibility of the effects. Day 15 of gestation was chosen for this 
model because previous fetal programming studies have shown that exposure 
during the third trimester, usually gestational days 15 to19, induce observable 
changes in offspring [22], [23], [166], [167]. Only a one-time dose was given at 
day 15 of gestation. It’s a possibility that spreading the radiation treatments out 
over 3-4 days and having an accumulation dose of 1000 mGy rather than a 
one-time whole-body irradiation would alter the outcome. The first exposure, 
because it would be significantly less than 1000 mGy, may act like a primer to 
each subsequent dose reducing the negative effects on the fetus.  
The time point chosen to test for alterations is also important. Studies 
have shown that changes in the offspring from fetal programming appear at 3 
months of age and persist to 18 months of age with increasing severity of 
disease and metabolic dysfunction with age [26], [168], [169]. The metabolic 
alterations observed in this study are not a result of aging because the mice 
are only 4 months old and considered young adults. 
The second factor that affects the measures is if the animals are in fed 
state or fasted. In fed state, or postprandial, insulin has been released stimulating 
glycogen synthesis and suppressing gluconeogenesis [170]. Fasting would 
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reduce variability but it would also stimulate b-adrenergic signaling and increase 
fatty acid release [171]. Fasting the animals prior to dissection and blood 
collection would have reduced variability but could not represent a normal 
metabolic status of the mice. Because the animals were in fed state for our study, 
it is not surprising that there is a huge amount of variation in the expression of 
phosphorylated Akt and GSK. Fed state would also explain why the plasma 
triglyceride concentrations vary significantly. However, fed state demonstrates 
glucose uptake and metabolism in a normal state which is important for IBAT 18F-
FDG uptake measures. Also, it prevents the additional stress from fasting.  
It was not a surprise that sex differences were evident throughout this 
study. As expected the average body weights and tissue weights were higher for 
males than for females. However, sexual dimorphism continues to appear 
throughout the targets measured in this study. When measuring insulin 
resistance, female protein expression of SOCS3 and PEPCK increased with 
treatment whereas, the males showed the opposite trend and protein expression 
decreased (Figures 8 & 9). Plasma triglyceride concentration was higher in the 
males and male hepatic triglyceride content increased with treatment whereas 
females showed no difference (Figures 10 & 11). The significant differences 
between males and females seen in the results of this study are not surprising 
based on previous fetal programming literature that have found sex differences in 
cardiovascular and metabolic function [172], [173]. The changes seen may be a 
result of differences in hormone concentrations between males and females. All 
sex hormones are present in both male and females. In females, the human 
estrous cycle is 28 days and rodents have a 4-day estrous cycle. Depending on 
the time point in the estrous cycle, protein expression in the liver and brown 
adipose may vary because of the changes in hormone levels. Figure 20 shows 
fluctuations in estrogen, progesterone, luteinizing hormone (LH), and follicle-
stimulating hormone (FSH) during one cycle in humans and rodents. These four 
hormones peak at different times during the cycle. Shen and Shi 2015, review 
the different sex hormones and their roles in glucose and lipid homeostasis in the 
liver [174]. Fernández-Pérez et al. 2013, discuss responses of the liver to 
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estrogen and growth hormone that result in sexual dimorphism [175]. The effects 
of estrogen on the liver can be direct or indirect through growth hormone (GH) 
function or by influencing pituitary GH secretion. Various hepatic genes are up- 
or down-regulated by different patterns in GH and sex-steroids and can affect 
glucose and lipid metabolism [175]. There are still uncertainties about the roles of 





Figure 20. Changes in sex hormones during the human and rodent estrous 
cycles. Fluctuations in hormones levels of estrogen, progesterone, luteinizing 
hormone (LH), and follicle-stimulating hormone (FSH) occur during the (A) 4-day 
rodent estrous cycle and (B) 28-day human cycle. The grey bars indicate night 
(6pm to 6am). Taken from Staley and Scarfman 2005 [176], adapted from Neill 





Chapter 6. Conclusion  
An area of concern is the potential for long term effects on the offspring 
from prenatal radiation exposure. Sub-lethal doses of radiation in mice are 
assumed to be equivalent to low dose radiation exposure in humans. The effects 
on the offspring observed in this study from 1000 mGy whole-body irradiations on 
the dams, suggest that a one-time sub-lethal dose causes physiological changes 
in metabolic activity in the female liver based on increases in protein expression 
of targets of insulin resistance, SOCS3 and PEPCK. BAT uptake was 
significantly increased in the female offspring of irradiated dams and it is likely 
caused by b-adrenergic signaling and not insulin signaling from the non-
significant increase in UCP1 and phosphorylated GSK3b protein expression. 
Changes are significant at 4 months of age but may be exacerbated over time. 
This research supplements the need for better characterization of the effects of 
prenatal sub-lethal dose radiation exposure in mice and low dose radiation in 





Chapter 7. Future Directions 
The present study opens the floor for several additional studies to look 
at alterations in glucose metabolism from fetal programming caused by 
radiation. It is a possibility that the changes in metabolism observed in this 
study may have been exacerbated if the animals were older. Experimenting 
with animals at 6, 12, or 18 months of age would provide a better 
understanding of radiation fetal programming models. Examining the effects of 
a dose response of radiation on fetal programming would aid in understanding 
the threshold of metabolic changes in mice. Our lab, along with researchers at 
McMaster University are currently working on a dose-response study using 
Sham, 50 mGy, 300 mGy and 1000 mGy radiation doses in C57Bl/6J mice. 
Additionally, an attempt should be made to find a new western blot target for b-
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Chapter 9. Appendix  
9.1 List of Abbreviations  
 
Akt – protein kinase B  
ATP – adenosine triphosphate  
BAT – brown adipose tissue  
BMI – body mass index  
cAMP – cyclic adenosine monophosphate  
18F-FDG – 18F-flurodeoxyglucose 
FSH – follicle-stimulating hormone  
GH – growth hormone  
GSK3b – glycogen synthase kinase 3 beta 
HPA – hypothalamic-pituitary-adrenal  
IBAT – interscapular brown adipose tissue  
IRS – insulin receptor substrates  
IRS-1 – insulin receptor 1  
IRS-2 – insulin receptor 2  
IUGR – intrauterine growth restriction  
LDR – low dose radiation  
LH – luteinizing hormone  
NAFLD – non-alcoholic fatty liver disease  
pAkt – phosphorylated protein kinase B  
PET – positron emission tomography 
pGSK3b - phosphorylated glycogen synthase kinase 3 beta  
PKA – protein kinase A  
SOCS3 – suppressor of cytokine signaling 3 
SUVMAX – maximum standardized uptake value  
PEPCK – phosphoenolpyruvate carboxykinase  
PI3K – phosphatidylinositol 3-kinase  
SLDR – sub-lethal dose radiation 
UCP1 – uncoupling protein 1  
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WAT – white adipose tissue  
 
9.2 FDG Dilution Calculations 
1. Measure activity of received sample. If in a vial, transfer to a syringe.  
2. Obtain concentration based on the activity measurement and volume (μCi/ml). 
3. Want final concentration of 300μCi/ml. Determine saline volume and FDG 
volume to acquire the desired concentration.  Ci (μCi/ml) Vi (ml) = Cf (300 
μCi/ml) Vf (1ml)   
Ex. To make 1 ml at 300uCi/ml: 
1180μCi/ml x Vi = 300μCi/ml x 1ml 
Vi = 300μCi / 1180μCi/ml 
 
4. With a new syringe take up saline volume first (1000μl-Vi) and then the FDG 
volume (Vi).   
5. Eject this into a new eppendorf tube and take up into the syringe again for 
injection.   
6. Check actual activity (concentration) present and determine amount to inject 
20μCi into the mouse. 
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9.3 Western Blot SOP: Lees Lab  
 
Day 1 - Gel Preparation and Running 
 
What you need: 
-gel apparatus with sponges (bench) 
-glass plates (2 sized (1.5mm), 2 short plates) (bench) 
-2 green plate holders (bench) 
-combs same size as glass plates (bench) 
-2x 50mL beakers (bench) 
-1x 50mL tube 
-10ml serological pipettes  
-2 transfer pipettes 
-Distilled water (DW) 
-1.5M Tris pH 8.8 (4oC) 
-0.5M Tris pH 6.8 (4oC) 
-10% SDS (bench) 
-40% acrylamide (4oC)  
-Ammonium persulfate (APS, 4oC) 
-TEMED (chemical storage cabinet) 
-20% methanol (bench) 
-0.1% SDS (bench) 
-standard ladder (molecular marker) (-20oC) 
-gel running apparatus and container (bench) 
-10ml syringe with needle 
 
*First remove samples from -80oC to thaw on ice. If a white precipitate is present 
after thawing, place samples at 37oC (using a heat block) until they are clear. 
This should only take a few minutes)* 
 
1. Obtain glass plates from drying rack on bench. If there is anything to clean 
off, use a kimwipe with DW 
2. Place glass plates in green holders with the doors open, making sure both 
plates lay flush with the surface of the bench, and with each other. Next, 
while applying slight pressure to the tops of the glass plates, close the 
doors. 
3. Place the well combs between the glass plates. Measure 11mm from the 
bottom of the well comb and place a mark. This is your pour line for your 
gel. Remove the combs and set aside. 
4. Prepare 10% APS in a 1.5ml eppendorf tube: add 0.1g APS (kept at 4oC) 
to 1ml DW. Triturate until dissolved. Make fresh daily. 
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5. Prepare your separating gel in a 50ml beaker with a stir bar. Your gel 
percentage depends on the weight of your target protein. Use the chart 






5% 7.5% 10% 12% 15% 
Distilled Water 12.3 10.93 9.68 8.68 7.18 
1.5M Tris, pH 
8.8 
5 5 5 5 5 
10% SDS 0.2 0.2 0.2 0.2 0.2 
40% 
Acrylamide 
2.5 3.75 5 6 7.5 
 
The percentage of acrylamide determines the percentage of gel you are making. 
So, if you have 30% acrylamide to start, you will need to adjust volumes 
accordingly. For example, for a 10% gel, you will need 6.67ml of 30% 
acrylamide, and 8.01ml of DW. The DW is to make up the final volume of the 





6. Once the stock components are mixed for the appropriate separating gel 
percentage, place the glass plates that are in the green holders onto the 
sponges of the gel apparatus. Clip them in. Ensure they are sitting flush 
on the sponges. 
7. *See note below. Place the beaker on a stir plate, mixing gently so as not 
to introduce bubbles. While mixing, quickly add 100ul 10% APS and 20ul 
TEMED. Allow to mix for 30 more seconds. 
8. Using a transfer pipette, pipette gel mixture quickly between the plates, 
moving back and forth between the two sets of plates after each pipette-
ful. Fill each set of plates to your marker line. 
9. Carefully overlay the separating gel with 20% methanol using a syringe. 
Allow to polymerize for 30 mins. *Tip: leave your transfer pipette in your 
beaker containing left over gel solution. If this is polymerized after 30 
minutes, your gel between the plates will be too. 
10. During this polymerization, mix your stock components for your stacking 
gel in a 50ml beaker containing a stir bar: 




Distilled Water 12.68 
0.5M Tris, pH 
6.8 
5 
10% SDS 0.2 
40% Acrylamide 2 
                                            Note the use of a different Tris buffer 
 
11. Once the gel is polymerized, pour the methanol down the sink and rinse 
the empty area between the plates three times with 0.1% SDS in a syringe 
(keep gels on the apparatus during this time). Ensure all SDS is emptied 
from this area by tilting the apparatus to the side and holding kimwipes to 
the top edge of the glass plates. 
12. Place the beaker on a stir plate, mixing gently. While mixing, quickly add 
100ul 10% APS and 20ul TEMED. Allow to mix for 30 more seconds. 
13. Using a transfer pipette, overlay the separating gel with the stacking gel 
solution, filling to the top of the plates. Insert comb on an angle slowly so 
as not to introduce bubbles or displace too much gel solution. Allow to 
polymerize for 30 mins 
 
*Note: If a vacuum degasser system is available, make up both the separating 
and stacking gel solutions in their beakers with stir bars (without the APS and 
TEMED), mix briefly on the stir plate and place both beakers into the degasser. 
Put the lid on and turn the vacuum pump on. Leave for 20 minutes to remove the 
air from the solutions. After 20 minutes, turn the pump off, remove the separating 
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gel, and while gently mixing on the stir plate, continue as for step 7. While the 
separating gel is polymerizing, put the lid back on the degasser to protect the 
stacking gel.  
 
14. Put your molecular marker (ladder) on ice 
15. Prepare your 1X Running Buffer as described in the Buffers section. This 
can be prepared in advance and stored at 4oC 
16. Once the gel is polymerized, remove the combs by pulling them straight 
up and out. Remove the glass plates carefully from the holders and place 
them onto the middle section of the apparatus (containing the electrodes). 
The short plates of each set should be facing each other. Place this 
section into the beige middle part with clear “doors”. The doors should be 
open while the electrode is being inserted. Apply gentle downward 
pressure to the electrode section while closing the doors. Place this in the 
clear container. 
17. Fill the middle section between the two gels with 1X Running buffer. Next, 
fill the clear container half way 
18. Fill a Styrofoam box with ice. Create a spot to put the gel container. Place 
the gel container in this spot and push the ice against the sides of the 
container. 
19. Begin loading your samples and ladder into the wells of the gel. You 
should load the wells of the gel closest to you first, and then turn the whole 
Styrofoam box to load the other gel. 
Typically, 5ul of ladder is loaded into the first well on your left. All wells 
should be filled to ensure the samples run straight down. 
20. Once all samples are loaded, place the lid onto the container (black to 
black electrode, red to red electrode). Plug the cords into the power supply 
and turn on. Turn the voltage up to 200V and press the button that looks 
like a man running. Make sure to observe bubbles in the running buffer, 
signifying the gel is running. 
21. The samples are condensed into a solid blue line while they run through 
the stacking gel. This ensures that all samples enter the separating gel at 
the same time, and therefore have the same amount of time to run 
through the gel. 
22. Allow your gel to run until the blue dye front completely runs off the bottom 
of the gel. This typically takes just over 1 hour. While this is happening, 
gather your transfer supplies and make fresh 1X Transfer Buffer, as per 
the Buffers section. This can be made in advance and stored at 4oC. 
 
Gel Transfer 
What you need: 
-transfer apparatus and container (bench) 
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-2x cassettes (bench) 
-2 plastic containers for soaking filter paper, sponges, and membranes (bench) 
-2 plastic containers for soaking the gels (bench) 
-4x black sponges (bench) 
-4x filter paper (bench) 
-2x nitrocellulose membrane (bench) 
-flat forceps (bench) 
-1x transfer buffer (4oC) 




23. Once the gel is finished running, bring the entire container to the sink and 
dump out the running buffer. Do not reuse this buffer. Disassemble the 
apparatus to remove the glass plates. 
24. Using the gel wedge, release the gel from the big plate so the gel is kept 
on the short plate. Cut the stacking gel off using the wedge and discard. 
Make a nick in the top left corner (usually the corner containing your 
ladder). 
25. Add 1x Transfer buffer to a container. Place the short plate with the gel on 
it over the top of the container. By allowing the buffer to make contact with 
the gel, it should take the gel off of the plate itself. If this does not work, or 
if the gel stayed on the big plate rather than the short plate, use the wedge 
to gently lift the gel off of the plate and place into the buffer. Repeat with 
second gel in a separate plastic container. 
26. Cut two membranes from the nitrocellulose roll using the filter paper as a 
size guide. Be careful not to touch the membrane with your gloves. Keep 
the blue paper on while cutting. 
27. In another plastic container, place one sponge, one filter paper, one 
membrane, one filter paper, one sponge, and fill with 1X Transfer buffer. 
Repeat for second membrane. 
28. Place all plastic containers on the belly dancer for 15 minutes, with slight 
agitation. This is necessary to equilibrate all components of the transfer 
“sandwich” 
29. While these components are soaking, wash the running apparatus. To do 
this, re-assemble without the glass plates and fill the container with DW. 
Discard and repeat for a total of 3 times. Allow to dry on the drying rack or 
paper towel. Do not hang. 
30. Assemble the sandwiches out of buffer on paper towel on the bench in the 
following order: clear side down, sponge, filter paper, membrane (move 
with forceps), gel (move with gel wedge, place so that cut corner remains 
on your left, ensure no bubbles), filter paper. 
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31. Use a 50ml tube to roll out any bubbles by starting in the middle of the 
filter paper and rolling outward. Repeat in opposite direction. Complete the 
sandwich by placing the second sponge onto the filter paper. Close the 
sandwich and repeat with the second one. 
32. Place the sandwiches in the centre of the transfer apparatus with the black 
side of the cassettes facing the black side of the apparatus. Place the 
apparatus in the clear container (same one used for running of gel), add a 
stir bar, and place the ice pack in the unfilled space in the container. 
33. Fill the container up to the edge with fresh 1X Transfer buffer  
34. Move the apparatus to the clear door fridge onto the stir plate. Turn the stir 
plate on to low, making sure the stir bar moves easily. Place lid on top, red 
to red electrode and black to black electrode. 
35. Turn the power supply on to 30V and run overnight. 
 
 
Day 2 – Ponceau S, Blocking, and Primary Antibody 
What you need: 
-2x plastic containers (bench) 
-flat forceps (bench) 
-scalpel (bench) 
-Ponceau S stain (bench, in the dark) 
-0.1M NaOH (bench) 
-1XTBST (bench) 
-1 clear plastic sheet (bench) 
-Blocking Solution 
-primary antibody (storage conditions dependent on antibody) 
-50ml conical tube 
 
36. Press stop on the power supply, turn off the stir plate and return the 
apparatus to the bench. 
37. On paper towel on the bench, open the sandwich (black side down) and 
cut the membrane to size using the scalpel, following the outline of the gel 
below it. If the transfer was successful, you will see the ladder on the 
membrane. Cut the nick in the corner again and flip the membrane over so 
that the nick is now on your left and place in a container. To keep track of 
which side is which, this nick should always be on your left, the side with 
your ladder. Repeat with the second sandwich. 
38. Rinse the membranes with DW quickly then discard and add Ponceau S 
to the container (enough to cover the membrane). Place on belly dancer at 
low speed for 5 minutes. 
39. During this staining, wash the transfer apparatus as you did the running 
apparatus. Allow to dry on the drying rack. 
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40. Discard the Ponceau stain down the sink and rinse the membranes with 
DW until all residual background red is gone, and only red bands remain. 
Scan this image on the computer.  
a. Open Canoscan 
b. Ethanol the scanner surface 
c. Lay membranes down on the surface, ensuring no bubbles 
d. Lay a clear plastic sheet over the membranes and close the 
scanner 
e. Select “Scan1”, source=platen, save to your file, click “ok” 
f. After the scan completes, the image is saved automatically. Check 
to make sure the picture is clear before destaining the membrane 
g. Ethanol the scanner surface again. 
41. Destain the membranes by adding 0.1M NaOH to the container with 
agitation. It should destain within minutes. 
42. Discard and rinse with DW, then wash the membrane for five minutes on 
the belly dancer at medium speed in 1XTBST (recipe in Buffers section, 
this can be made in advance and stored at room temperature) 
43. During this wash step, prepare your blocking solution. Make sure to check 
the antibody information sheet of the antibody you will use to choose the 
appropriate blocking solution. Typically, 5% milk is sufficient, but BSA is 
also sometimes used. Skim milk is in a bag in the weigh room and BSA is 
kept at 4oC. Make this fresh daily in 1XTBST. Typically, 25ml is used per 
membrane. 
44. Once the wash step is complete, discard the 1XTBST and add blocking 
solution to the container. Place on the belly dancer at room temperature 
on a low speed for 1 hour. 
*Tip: If after you complete your western it comes out with nonspecific 
antibody binding, you can increase your blocking percentage to 8% to 
attempt to eliminate that. 
45. Just before the blocking step is complete, make up the primary antibody in 
a 50ml tube. The antibody information sheet should suggest a starting 
concentration for the antibody, as well as what to make it in. Typically, 5ml 
of antibody solution (5% milk or BSA made in 1XTBST) is made per 
membrane.  
46. Once the blocking step is complete, if you are probing for multiple targets 
that run far enough apart on the gel, you can cut your membrane into two 
pieces and probe two at once. If you do this, you will cut using the scalpel, 
and use the smaller sectioned container. Each half of the gel should fit 
perfectly into the sections, allowing for the use of 2.5ml of antibody 
solution. If you do not cut the membrane, move the membrane to the 
smaller coloured containers that fit the whole membrane perfectly. This 
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container requires 5ml of antibody solution. Place the container of choice 
on the rocker in the fridge (4oC) at a low speed. Leave overnight. 
 
The information sheet that 
comes with your antibody has 
suggested blocking 
percentages as well as 
antibody concentrations. It 
also lists species reactivity, 
meaning which animal 
species they can detect. 
Ensure the antibody you 
choose is specific for the 
species of your sample. Some 
primary antibodies are 
specific to multiple animals. 
Your secondary antibody is 
made to target your primary 
antibody based on the animal 
that your primary antibody 
was made in. So, if your 
primary antibody is a goat 
anti-rat IL-6, it is detecting rat 
IL-6 in your sample, and was made in a goat. This means your secondary 
antibody must be anti-goat. Do not use a secondary antibody that is specific to 
your sample species. This will cause unspecific binding. So, if your sample 
comes from a rat, your secondary should not be anti-rat, and therefore your 
primary cannot be made in a rat. 
 
Day 3 - Secondary antibody 
What you need: 
-2x plastic containers 
-1XTBST (bench) 
-Blocking solution (made fresh daily) 
-secondary antibody (storage conditions dependent on antibody) 
-15mL tubes (bench) 
 
47. Remove membranes from the fridge and place in plastic containers. Add 
1XTBST to cover and wash the membranes for a total time of 25 mins 
(medium speed on the belly dancer), changing the buffer every 5 minutes 
(discard down drain). 
48. During the last wash, prepare the secondary antibody as per the antibody 
information sheet. Typically, 25ml of solution (usually in 5% milk made in 
1XTBST) is used per membrane. 
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49. Following washes, discard the 1XTBST and add the secondary antibody 
solution. Place on belly dancer for 1 hour at room temperature at a low 
speed. 
50. Discard the secondary antibody solution and perform wash steps as per 
step 47. 
51. During the final wash steps, prepare your detection solution (If using 





Enhanced Chemiluminescence (ECL)  
 
What you need: 
-1XTBST (bench) 
-1.0M Tris pH 8.5 (4oC) 
-DW 
-30% H2O2 (4oC) 
-Coumeric acid - light sensitive (-20oC) 
-Luminol - light sensitive (-20oC) 
-1x clear plastic sheet (bench) 
-2x 50mL tubes, one wrapped in tinfoil (bench, tinfoil in autoclave room) 
-plastic wrap, taped flat to the bench 
-kimwipes 
-1ml pipette and tips 
-flat forceps for membrane handling 
 
*Take out coumeric acid and luminol, wrap in tinfoil and thaw on bench 
 
Label two 50ml tubes as “Solution 1” and “Solution 2”. Add components listed 
below and keep solution 2 covered with tinfoil. 
 










a. Turn on the ChemiDoc imager (2 things to turn on: black box beside the 
computer first, then big beige imager) 
b. Open “Quantity One” on the computer, press “EPI White” on the imager 
Component Volume Component Volume 
1.0M Tris pH 8.5 2mL 1.0M Tris pH 8.5 2mL 
30% H2O2 12uL 90mM Coumeric 
acid 
88uL 
Distilled Water 8mL 250mM Luminol 200uL 
  Distilled Water 8mL 
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c. In the program, “File” > “ChemiDox XRS” > “Select” > “Custom” > 
“Western MWM” 
d. Change the filter on the imager to the middle position (black stick on top) 
 
52. After the final wash, discard the wash buffer. Using the flat forceps, move 
the membranes to the plastic wrap.  
53. Pour ECL solutions together into one 50ml tube and mix by inverting. 
Pipette the mixed ECL directly onto the membranes, being sure to cover 
every part of it. Continue for one minute. 
54. Dab excess ECL solution from membranes onto kimwipe by touching the 
corner of the membrane to the kimwipes, handling with the flat forceps. 
Place membranes onto clear plastic sheet and move to imager 
55. Open drawer on imager to place membranes on sheet inside. In program, 
click “Live Focus” > “Freeze” (once it is in the appropriate position; it can 
be focused using the buttons on the imager) > “Auto Expose” > “Save”. 
You now have an image of your ladder saved which is used to determine 
band size. 
56. To detect your chemiluminescence, “File” > “ChemiDox XRS” > “Select” > 
“Custom” > “Sean Bryan Western”, turn off the “Epi White” on the imager, 
change the filter to the first position (a O), click “Live Acquire”, and fill in as 
300 second exposure with photos taken every 60 seconds. Click “Save” 
and it will run. This time can be altered based on your target protein and 
how easily it can be imaged. You will have an idea of how well this timing 
is working after the first minute when the first picture pops up. 
57. Once all images have been taken, the membrane can be discarded or 
stored at 4oC in 1XTBS (1XTBST without the Tween 20) until a decision is 
made. The membrane can be stripped and re-probed for another target if 
necessary. 
 
 
 
